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Ion channels are intrinsic membrane proteins that control the flow of specific 
ions across the cellular membrane. All ion channels are large transmembrane proteins. 
In living cells there are 300 types of ion channels (Gabashvili et al., 2007). Channels 
are ion selective and can differentiate between size and charge of the ions. Ion 
channels are classified based on the physical and chemical modulator of their gating 
properties. Some of the important groups of ion channels are listed below. 
 
- Ligand-gated channels 
- Voltage-gated channels 
 - Second messenger-gated channels 
 - Mechanosensitive channels 
- Gap junctions 
 
Voltage-gated ion channels in the cell membrane possess three different states: closed, 
open and inactivated. Ion channels in the cell membrane open or close depending on 
the cell membrane potential. Specific ions flow down their electrochemical gradient, 
when a channel is in an open state. The ion channel protein adopts different 
conformational states depending on the membrane potential. Ionic current is measured 
from the ion flow through an open channel. The best method to study this process is 
the patch clamp technique.  




1.1.1 Cardiac action potential 
 
The cardiac action potential is necessary for the electrical conduction system 
of the heart. Action potential of a single cardiac myocyte and the electrophysiological 
and mechanical function of the heart are interdependent. Various ion channels are 
responsible for the cardiac action potential. 
The action potential is divided into five distinct phases corresponding to clearly 
recognizable landmarks in its contour. 
 
Phase 0: Fast depolarization or upstroke 
Phase 1: Fast initial repolarization 
Phase 2: Plateau 
Phase 3: Fast terminal repolarization 
Phase 4: Electric diastole 
 
 
Figure 1: Representation of an action potential from a ventricular myocardial 
cell showing all the possible currents responsible for different phases. 
An action potential is generated when the membrane potential is partially depolarized 
from the resting potential to the threshold potential.   




Table 1: Major currents during the cardiac ventricular action potential. 
 
 
1.2 Voltage-gated ion channels 
 
                  Hodgkin and Huxley performed experiments on the ionic events 
responsible for the action potential, and with their classical equations they described 
the conductance and currents quantitatively (Hodgkin and Huxley, 1952b). The rising 
phase generation in the action potential was analyzed and explained by a conductance 
to sodium ions. 
The eel electroplax, was the source where the first voltage-dependent ion channel was 
isolated and purified (Agnew et al., 1978). Several years later the sequence for the eel 
sodium channel was deduced from its mRNA (Noda et al., 1984). The voltage-
dependent potassium channel (KvAP) from Aeropyrum pernix is the first X-ray 
crystallographic structure solved at a resolution of 3.2 Å (Jiang et al., 2003). Till now 
this forms the template for modelling other voltage-gated sodium, calcium and 
potassium channels. This research was awarded with the Nobel Prize in 2003. A basic 
pattern emerged from all these sequences: the functional channels are made up of four 
subunits (K
+






In this thesis I will focus on the voltage-gated sodium channel. 
 
Ions Current Protein Gene Phase/Role 
Na
+
 INa NaV1.5 SCN5A 0 
Ca
2+
 ICa(L) CaV1.2 CACNA1C 0-2 
K
+
 Ito1 KV4.2/4.3 KCND2/KCND3 1, notch 
K
+
 IKs KV7.1 KCNQ1 2,3 
K
+
 IKr hERG (KV11.1) KCNH2 3 
K+ IK1 KIR2.1/2.2/2.3 KCNJ2/ KCNJ12/KCNJ4 3,4 




1.3 Voltage-gated sodium channels 
 
              Voltage-gated sodium channels (NaV) belong to a family of membrane 
proteins that selectively conduct sodium due to changes in membrane potential. 
Sodium channels have various functional and pharmacological properties in different 
tissues and species (Mandel, 1992). Some sodium channels are not voltage-gated, 
such as the epithelial sodium channel (ENaC), which is responsible for sodium 
transport, and it is unrelated to other NaV channels (Catterall, 2000; Yu and Catterall, 
2003).  
 
1.3.1 Structure of voltage-gated sodium channels 
 
              NaV channels have a large, complex multimeric structure that is comprised of 
a core α-subunit and auxiliary function modifying β-subunits (Catterall, 2000) (Figure 
2). These auxiliary subunits are involved in cellular signalling, channel trafficking, 
cell adhesion, stability of the membrane, gating modulation, and they may be targets 
for proteases involved in disease (Fahmi et al., 2001; Isom, 2001; Isom et al., 1994; 
Isom et al., 1992; Isom et al., 1995; Morgan et al., 2000; Zhou et al., 2000). Although 
NaV channels have auxiliary subunits, channel function, such as channel opening, ion 
selection and inactivation, is controlled by the core α-subunit. The central core is 
formed by a four domain-folding (DI-DIV) pattern, which determines the ion 
selectivity and conductance. Each domain is composed of six transmembrane helices 
(S1-S6). The S4 of each domain is the voltage sensor; it contains a distinct amino acid 
sequence, which has a positively charged residue followed by two hydrophobic 
residues. The re-entrant P-loop connecting S5-S6 forms a narrow and selective ion 
pore (Kass, 2006). Two negatively charged amino acids are present in an analogous 
position in all four domains, which form the receptor site and selectivity filter. The 
mammalian sodium channel resembles a subunit from the potassium channel of 
primitive bacteria (Ren et al., 2001). Substitution of a lysine at position 1,422 in 
repeat III and/or an alanine at position 1,714 in repeat IV of rat sodium channel II 
alters ion selectivity such that the channel takes on properties of a calcium channel. 
These data suggest that these residues constitute a portion of the selectivity filter 
(Heinemann et al., 1992).  








Figure 2: A schematic representation of the voltage-gated sodium channel 
showing all four domains (DI-DIV) of the α-subunit and two β-
subunits. 
Each domain has 6 transmembrane helices with a voltage senor S4 (in yellow) and 
two pore lining segments S5 and S6 (in green). Blue circles in the intracellular loops 
of domains III and IV indicate the inactivation gate IFM motif and its receptor (h, 
inactivation gate); P, phosphorylation sites (in red circles: sites for protein kinase A; 
in red diamonds: sites for protein kinase C); ψ, probable N-linked glycosylation sites. 
Adapted from Yu and Catterall (2003). 
  




1.3.2 Sodium channel gating 
 
The sodium channel gates between three functional states: resting, active and 
inactivated – in a manner controlled by the membrane potential (Hodgkin and Huxley, 
1952a). Channel opening (activation) is caused by the outward movement of the 
voltage sensors (S4) in each of the four domains in response to depolarization of the 
membrane potential. The movement of the voltage sensors is somehow coupled to 
opening of the channel, allowing entry of Na
+
 ions. The short duration of channel 
activation is due to rapid inactivation. Inactivation is controlled by amino acids within 
the cytoplasmic loop between domains III and IV (George, 2005). Sodium channels 
undergo a slow inactivation if the membrane is depolarized for a long duration (Vilin 
and Ruben, 2001). This slower inactivation affects the amount of channels in the 
activation state. The detailed molecular mechanism of voltage-gated sodium channel 
gating is documented (Catterall, 1991, 2000; Denac et al., 2000; French and Horn, 
1983; Hodgkin and Huxley, 1952a; Kuhn and Greeff, 1999; Marban et al., 1998; 
Mitrovic et al., 1995; Morgan et al., 2000; Romine et al., 1974; Tomaselli et al., 1995; 
Yang et al., 1996). 
 
1.3.3 Voltage-gated sodium channel subtypes 
 
              There are nine sodium channel subtypes that are categorised by amino acid 
sequence and channel function (Table 1). These nine subtypes are broadly classified 
into three groups. The first group of channels is located in the central nervous system 
(CNS) and is comprised of the NaV1.1, NaV1.2, NaV1.3 and NaV1.6 sodium channels. 
The NaV1.3 channel is highly expressed in the dorsal root ganglion (DRG). All four of 
the sodium channel subtypes are located on chromosome 2 (Catterall et al., 2005; 
Malo et al., 1994), and they are sensitive to tetrodotoxin (TTX) with a nanomolar IC50 
value (Goldin, 2001). The next group of sodium channel subtypes is more diverse and 
is present on chromosome 3. This group is comprised of the cardiac NaV1.5 channel 
subtype and the nociceptive neuron channel subtypes NaV1.8 and NaV1.9. These latter 
subtypes are TTX-resistive with micromolar IC50 values (Goldin, 2001). Single amino 
acid change from aromatic tyrosine or phenylalanine in chromosome 2 located 
subtypes to hydrophilic cystine, as present in NaV1.5, reduces the TTX sensitivity 200 
fold (Satin et al., 1992). On the other hand, change from phenylalanine to serine, 




which is present in NaV1.8 and NaV1.9, results in even higher resistance to TTX 
(Sivilotti et al., 1997). TTX-resistant subtypes differ from TTX-sensitive subtypes in 
that they have slow inactivation kinetics and a single amino acid substitution in the 
pore-lining region of domain I (Catterall et al., 2005; Rogers et al., 2006). The third 
group of sodium channel subtypes is the intermediate group, which is composed of 
the TTX-sensitive skeletal muscle channel NaV1.4 and the DRG and sympathetic 
ganglion sodium channel NaV1.7 (Catterall et al., 2005; Rogers et al., 2006).  
Sodium channels remain important targets for the development of novel drugs to treat 
many neurological, muscular and cardiac disorders. To date, numerous isoforms have 
been identified. Yet, it is unclear whether there are additional sodium channel 
isoforms. Advances in molecular biology have made it possible to discover channel 
mutations that occur in clinical disorders. However, additional analysis of the 
signalling pathways and molecules that modulate sodium channels is necessary. 
Proteins that are associated with sodium channels and the site of interaction should be 
identified in order to have a better understanding of channel function. Phenotype-
based research should be performed to elucidate the role of sodium channels in 
physiology and disease. Lastly, since there is no crystal structure of mammalian 
sodium channels, understanding the structure-function relationship of sodium 
channels is hindered. Recent studies have shown that the sodium channel is far more 






              Research of the molecular properties of sodium channels has elucidated 
mutations that cause multiple inherited hyper-excitability diseases in humans – 
considerably unexpected since a priori mutations might be expected to produce 
primarily hypo-excitability. These disorders are termed channelopathies. The first 
channelopathy involving sodium channels was found in skeletal muscle. Other 
channelopathies have been reported in cardiac and neuronal subtypes. A brief 
overview of review articles and original papers dealing with the various 
channelopathies is given in Table 2, followed by reviewing very recent publications in 
the subsequent section.  




Table 2: Different sodium channel isoforms and their associated channelopathies. 
Isoform Gene Location Channelopathies References 
NaV1.1 SCN1A CNS and 
DRG 
 Generalized epilepsy with 
febrile seizure  
 Dravet syndrome 
(Heron et al., 2007; Lossin, 2009) 
NaV1.2 SCN2A CNS and 
DRG 
 Generalized epilepsy with 
febrile seizure 
 Dravet syndrome 
 Benign familial neonatal-
infantile seizure 
(Herlenius et al., 2007; Heron et al., 
2007; Misra et al., 2008; Sugawara 
et al., 2001) 
 
NaV1.3 SCN3A embryos, 
DRG and 
CNS 
 (Chen et al., 2000; Cummins and 
Waxman, 1997) 




 Paramyotonia congenita  
 Hyperkalemic periodic 
paralysis  
 Hypokalemic periodic 
paralysis 2  
(Heine et al., 1993; Orrell et al., 
1998) 
(Koch et al., 1995; Ptacek et al., 
1992; Wu et al., 2001) 
(Bendahhou et al., 1999; Ptacek et 
al., 1993) 
(Bendahhou et al., 2000; Bulman et 
al., 1999; Davies et al., 2001) 
NaV1.5 SCN5A heart, 
embryos 
and DRG 
 Long QT syndrome 
 Brugada syndrome 
 Conduction dysfunction  
 Sinus node dysfunction 
 SIDS 
 Atrial fibrillation 
(Bennett et al., 1995; Goldenberg 
and Moss, 2008; Heron et al., 2009) 
(Benito et al., 2009; Brugada et al., 
2009; Chen et al., 1998) 
(Schott et al., 1999) 
(Benson et al., 2003; Lei et al., 
2008) 
(Makielski, 2006; Skinner et al., 
2005; Wedekind et al., 2006) 
(Ellinor et al., 2008; McNair et al., 
2004; Olson et al., 2005) 
NaV1.6 SCN8A DRG and 
CNS 
In jolting mice- inherited 
cerebellar ataxias 
(Kohrman et al., 1996) 




 Primary erythermalgia 
 Paroxysmal extreme pain 
disorder 
 Insensitivity to pain  
(Drenth et al., 2005; Han et al., 
2006; Harty et al., 2006; Yang et 
al., 2004) 
(Fertleman et al., 2006) 
(Cox et al., 2006) 
NaV1.8 SCN10A DRG  Neuropathic injury of DRG 
 Trigeminal ganglia model of 
neuropathic pain 
 In human cases radicular 
pain 
(Boucher et al., 2000; Coward et 
al., 2000; Dib-Hajj et al., 1998) 
(Eriksson et al., 2005) 
(Abe et al., 2002; Coward et al., 
2000) 
NaV1.9 SCN11A DRG and 
CNS 
 Neuropathic injury of DRG 
 Trigeminal ganglia model of 
neuropathic pain 
 In human cases radicular 
pain 
(Boucher et al., 2000; Coward et 
al., 2000; Dib-Hajj et al., 1998) 
(Eriksson et al., 2005)  
(Abe et al., 2002; Coward et al., 
2000)  




1.4.1 Cardiac sodium (SCN5A) channelopathies 
 
              Impulse conduction in the atria, His-Purkinje system and the ventricle is 
sustained by the transient increase in sodium permeability (Hoffman and Cranefield, 
1960). Cardiac sodium channels are the target of antiarrhythymic drugs (Grant et al., 
1984; Hondeghem and Katzung, 1977). Disturbances in conduction and life-
threatening arrhythmias are caused by decreased sodium channel function (Cascio, 
2001; Tomaselli and Zipes, 2004).  
NaV1.5 is a 2016 amino acid protein. Mutations in SCN5A, which encodes the 
primary sodium channel in cardiac tissues, cause sodium channel dysfunction and are 
associated with a number of unrelated arrhythmic syndromes, such as long QT 
syndrome (LQTS) (Bennett et al., 1995; Goldenberg and Moss, 2008), Brugada 
syndrome (BrS) (Benito et al., 2009; Brugada et al., 2009; Chen et al., 1998), 
conduction dysfunction (Schott et al., 1999), sinus node dysfunction (Benson et al., 
2003; Lei et al., 2008), sudden infant death syndrome (SIDS) (Makielski, 2006; 
Skinner et al., 2005; Wedekind et al., 2006) and atrial fibrillation (Ellinor et al., 2008; 
McNair et al., 2004; Olson et al., 2005). 
Sodium channel mutation causes cardiac arrhythmia by one of the two mechanisms: 
a) Loss-of-function (LoF) mutations: The consequences of these mutations are non-
functional channels or rapidly inactivating channels. This results in a decrease of 
available sodium current during the fast depolarization phase. 
b) Gain-of-function (GoF) mutations: These mutations cause an increase in 
inactivation reversibility in the late component of the sodium current. In addition, 
these mutations prolong action potential duration and the QT interval. 
 
 
1.5 Cardiac sodium channel splice variants 
 
Exons coding for the cardiac sodium channel subtype undergo alternative 
splicing which eventually can produce biochemically, pharmacologically and 
functionally distinct sodium channels (Choi et al., 2010; Gazina et al., 2010; Kerr et 
al., 2008; Makielski et al., 2003; Schirmeyer et al., 2010; Schroeter et al., 2010; Tan et 
al., 2005). Figure 3 shows different splice variants of the cardiac sodium channel. 






Figure 3: Structure of NaV1.5 splice variants. 
(A) Proposed membrane topology of NaV1.5. (B) Alternative splicing of NaV1.5 results in 
exon skipping (NaV1.5a, NaV1.5b, NaV1.5f), in alternative usage of the exon 18 splice 
acceptor site and the extension of this exon by a CAG trinucleotide coding for Q1077 
(NaV1.5c), in partial deletion of exon 17 (NaV1.5d), in the alternative usage of one of two 
exon 6 variants (NaV1.5e), in abnormal exon 27/exon 28 splicing (variants E28B, E28C) or in 
premature transcript termination (E28D; last amino acid is G1642). The original numbering 
system of hH1 with 2016 amino acids (Gellens et al., 1992) is used in the sequence 
numbering. Reproduced from Schroeter et al. (2010). 




1.5.1 Functional NaV1.5 splice variants 
 
NaV1.5a was the first functional splice variant with the deletion of exon 18, 
which encodes for 53 amino acids of the DII-III linker (Zimmer et al., 2002). This 
variant is a species–specific expression in the mammalian heart. It is not expressed in 
human, whereas it is expressed in pig, rat and mouse (Blechschmidt et al., 2008). 
Electrophysiological studies show similar kinetics to mouse NaV1.5 when expressed 
in HEK293 cells (Zimmer et al., 2002).  
NaV1.5c is the most abundant splice variant in the human heart. A glutamine at 
position 1077 by a 5′-extension of exon 18 (trinucleotide CAG), makes the splice 
variant NaV1.5c (Makielski et al., 2003). Electrophysiological properties of Q1077 
and ∆Q1077 were alike (Makielski et al., 2003). Recent studies show that this splice 
variant plays an important role in SCN5A channelopathies like LQTS and BrS 
(Cocquet et al., 2006; Wang et al., 2007). The predicted phosphorylation site for CK2 
(„Casein kinase 2‟, regulated through protein-protein interactions and changes in its 
concentration (Rodriguez et al., 2008)) is destroyed when Q1077 is included (Kerr et 
al., 2004). ∆Q1077 is the most abundant variant present in human heart. It is present 
in 45% of the human population (Makielski et al., 2003) (Table 3). Physiology of this 
splice variant is uncertain. 
NaV1.5d is a splice variant, with alternative exon 17 splicing as shown in Figure 3. 
Electrophysiological measurement shows that NaV1.5d significantly altered the 
kinetics, with depolarized steady-state activation and inactivation and 20% reduction 
in peak INa (Camacho et al., 2006; Schroeter et al. 2010). 
Functional splice variant NaV1.5e is present is human brain (Ou et al., 2005) and in 
human breast cancer cells (Brackenbury et al., 2007; Brackenbury et al., 2008; Fraser 
et al., 2005). NaV1.5e variant is alternative usage of „neonatal‟ exon 6a. Shift of the 
steady-state activation to more depolarized potentials, slower recovery from 
inactivation and reduced availability are the electrophysiological differences between 








1.5.2 Non-functional NaV1.5 splice variants  
 
Non-functional splice variant NaV1.5b is generated by deletion of exon 17 and 
18 which codes for the C-terminal end of DIIS6 that forms the large portion of the 
intracellular loop LDII-DIII (Zimmer et al., 2002). It is expressed in mouse heart but it is 
not expressed in rat, pig and human heart (Blechschmidt et al., 2008). 
NaV1.5f is a non-functional splice variant present in various rat tissues and in human 
brain. NaV1.5f is characterized by deletion of exon 24 and thus removal of 18 amino 
acids in the DIII pore region (Schroeter et al., 2010; Wang et al., 2009; Wang et al., 
2008).  
C-terminal truncated splice variants (E28B, E28C and E28D) of NaV1.5 were the 
splice variant which showed first evidence in the pathophysiology of the human heart 
(Shang et al., 2008; Shang et al., 2007). The mechanism of splicing is uncertain. All 
three novel C-terminal truncated splice variants were transcribed in human 
lymphoblasts, and one of them was expressed in human skeletal muscle (E28D). None 
of the truncated variants were observed in rats and mice (Schroeter et al., 2010; Shang 
et al., 2008; Shang et al., 2007). 
 
 
1.6 Src tyrosine kinase 
 
            Tyrosine phosphorylation plays a vital role in the regulation of a variety of 
biological responses, which includes cell proliferation, migration, differentiation and 
survival (Thomas and Brugge, 1997). The protein tyrosine kinase (PTK) encompasses 
a diverse spectrum of proteins which mediate the above responses, as well as the 
receptors which activate them (Thomas and Brugge, 1997). There are many different 
distinct families of tyrosine kinases which execute the responses that lead to complex 
extensive cross talk between different receptor pathways. One such large family of 
cytoplasmic tyrosine kinases which is capable of communicating with a large number 
of different receptors is the Src protein tyrosine kinase (Src PTK) (Brugge and 
Erikson, 1977). The prototype of Src was first identified as the transforming protein 
(v-Src) of the oncogenic retrovirus, Rous sarcoma virus (Brugge and Erikson, 1977). 
V-Src is the mutant variant of a cellular protein ubiquitously expressed and highly 




conserved over evolution. In 1978, two groups of researchers found that Src proteins 
possess protein tyrosine kinase activity, which led to deep investigation of Src on cell 
proliferation and its kinase activity (Collett and Erikson, 1978; Levinson et al., 1978).  
 
1.6.1 Members of Src tyrosine kinase and its cellular location 
 
Ten proteins were identified in this large Src PTK family which have structural 
features and significant amino acid sequence homology to Src. The ten members are 
Fyn, Yes, Yrk, Blk, Fgr, Hck, Lyn and the Frk subfamily proteins Frk/Rak and 
Iyk/Bsk (Brown and Cooper, 1996; Cance et al., 1994; Oberg-Welsh and Welsh, 
1995; Thuveson et al., 1995). The Src PTK is further divided into three major groups 
based on their expression. Src, Fyn and Yes are expressed in almost all tissues (Brown 
and Cooper, 1996). The second group consists of hematopoietic cell expressed Src 
PTK Blk, Fgr, Hck, Lck and Lyn (Bolen and Brugge, 1997). The third subgroup, 
Frk/Rak and Iyk/Bsk Src PTK, is expressed in epithelial-derived cells (Cance et al., 
1994; Lee et al., 1994; Oberg-Welsh and Welsh, 1995; Thuveson et al., 1995). Thus, 
Src-PTKs can function in many distinct cells and in distinct sub-cellular locations.  
 
1.6.2 Functional regions of Src tyrosine kinase 
 
Src PTKs are 52-62 kDa proteins composed of six distinct functional regions (Figure 




Figure 4: Organization of Src tyrosine kinase domain structure 
The Figure shows all 6 different functional regions as explained in the text. 
Reproduced from Boggon and Eck (2004).               
 





I. Src Homology (SH) 4 domain  
This domain is a 15-amino acid sequence which contains signals for lipid 
modification of Src PTKs. Glycine at position 2 is responsible for the addition 
of myristic acid moiety, which is involved in targeting Src PTKs to cellular 
membranes (Resh, 1993). The cysteine residues in this domain are subjected to 
palmitylation (Resh, 1993; Thomas and Brugge, 1997). 
II. Unique region 
The name suggests its properties; this domain is unique and distinct for each 
member. It is proposed that this domain is involved in mediating interactions 
with receptors or proteins that are specific for each family member (Morgan et 
al., 1989; Winkler et al., 1993). It is also speculated that this region is involved 
in modulating proteins: protein interactions or regulation of catalytic activity 
(Thomas and Brugge, 1997). 
III. SH3 domain 
SH3 domains of Src PTK are composed of 50 amino acids. It is very important 
for intra- and intermolecular interactions that regulate Src catalytic activity, 
Src localization and recruitment of substrates. All SH3 domains target a 
proline-rich core consensus motif P-X-X-P (Feng et al., 1994; Rickles et al., 
1995; Yu et al., 1994). Amino acids surrounding the prolines play a vital role 
in additional affinity and specificity for individual SH3 domains. Binding 
affinities of SH3 domains are in the micro-molar range. These affinities are 
strengthened in vivo by additional contacts with the target protein and other 
domains of Src (Cohen et al., 1995; Thomas and Brugge, 1997). 
IV. SH2 domain 
The SH2 domain is also an important domain involved in the regulation of the 
catalytic activity of Src PTKs, as well as the localization of Src and its binding 
proteins (Cohen et al., 1995; Pawson, 1995). All SH2 domains bind to short 
contiguous amino acid sequences containing phosphotyrosine. The specificity 
of individual SH2 domains lies in the 3-5 residues following the 
phosphotyrosine (Pawson, 1995). Structural analysis of SH2 revealed that the 
ligand-binding surface of SH2 domains is composed of two pockets. One 
pocket contacts the phosphotyrosine , the other pocket contacts the +3 amino 
acid residue following the phosphotyrosine (Songyang et al., 1993). 





V. Kinase domain (SH1) 
This domain possesses tyrosine Y-416, specific for protein kinase activity. The 
autophosphorylation site is very important for the regulation of kinase activity 
(Hubbard et al., 1994; Johnson et al., 1996; Knighton et al., 1991a; Knighton 
et al., 1991b). Phosphorylation of Tyr-416 stimulates complete activation of 
Src and provides a binding site for SH2 domains of other cellular proteins. The 
SH3 domain interacts with sequences in the kinase domain, as well as with 
sequences in the linker region that lies between the SH2 and kinase domain 
(Sicheri et al., 1997; Xu et al., 1997).  
VI. Short negative regulatory region  
This segment plays an important role in the activation of src kinase. It has the 
critical tyrosine residue Tyr 527. The SH2 domain interacts with pTyr 527 
(Src) and adjacent residues in the negative regulatory tail (Brown and Cooper, 
1996). Y527 in c-Src, and the corresponding tyrosine in other Src PTKs, are 
the primary sites of tyrosine phosphorylation in vivo. Kinase activity is 
reduced when pTyr 527 is phosphorylated and bound to the SH2 domain 
(Brown and Cooper, 1996). 
 
Apart from all these domains the very important SH2 and SH3 domains have four 
principal functions in the regulation of Src kinase (Brown and Cooper, 1996):  
1. They constrain the activity of the enzyme via intramolecular contacts.  
2. Proteins that contain SH2 or SH3 ligands can bind to the SH2 or SH3 domains 
of Src and attract them to specific cellular locations.  
3. Displacement of the intramolecular SH2 or SH3 domains results in activation 
of Src kinase activity.  
4. Proteins containing SH2 or SH3 ligands can enhance their ability to function 
as substrates for Src protein–tyrosine kinase. 
 
1.6.3 Structure of Src PTK and activation of tyrosine kinase         
 
The Src kinase domain consists of the characteristic bilobed protein kinase 
architecture as illustrated in Figure 5 (Glass et al., 1997; Xu et al., 1997). The human 




Src gene encodes a protein of 536 amino acids, and the chicken Src gene encodes a 
533-residue protein. The small amino-terminal lobe of the kinase consists of residues 
267–337 and is involved in anchoring and orienting ATP. This smaller lobe has 
mainly antiparallel β-sheet structure (Roskoski, 2004). Residues 341–520 form the 
large carboxyl-terminal lobe which is responsible for binding the protein substrate, 
and part of the ATP-binding site occurs in this lobe. It has predominantly α-helical 
structure (Roskoski, 2004). The cleft between the two lobes is the catalytic site for Src 
kinase. The two lobes move relative to each other and can open or close the cleft. 
Active site residues are from both the small and large lobes of the kinase; hence 




Figure 5: Ribbon diagram illustrating the structure of human Src. 
This figure is reproduced from Roskoski (2004) and Xu et al. (1999). 
 
The network controlling Src is a three step mechanism described by Harisson: the 
latch, the clamp, and the switch (Harrison, 2003).  
A latch is formed when SH2 domain binds to phosphotyrosine 527 in the C-terminal 
tail. Tyr-527 is phoshrylated by csk kinase (Nada et al., 1991). This latch in turn 
stabilizes the attachment of the SH2 domain to the large lobe. Then the SH3 domain 




contacts the small lobe. Prolines in the linker between the SH2 and kinase domains 
function as a motif that binds the SH3 domain and attaches the SH3 domain to the 
small kinase lobe. The assembly of the SH2 and SH3 domains behind the kinase 
domain is the clamp. This prevents the opening and closing of the cleft between the 
small and large lobes. The switch is the kinase-domain activation loop; the activation 
loop can switch between active and inactive conformations.  
 
1.6.4 Mechanism of Src activation 
 
Src tyrosine kinase is activated by unlatching, unclamping and switching. 
In the inactive state, Tyr 416, which is present in the activation loop, is segregated and 
is not a substrate for phosphorylation by another kinase (Roskoski, 2004). The protein 
is unlatched when phosphotyrosine 527 dissociates or is displaced from the SH2-
binding pocket. When the protein is unlatched the clamp no longer locks the catalytic 
domain in an inactive conformation (Harrison, 2003; Xu et al., 1999). This 
dissociation allows dephosphorylation by enzymes such as protein tyrosine 
phosphatase-α (PTPα) (Brown and Cooper, 1996). This in turn allows the activation 
loop to assume their active conformations. Tyr416 can then undergo 
autophosphorylation by another Src kinase molecule. Following autophosphorylation, 
the enzyme is stabilized in its active state (Roskoski, 2004). 
Studies show that substitution of Tyr-527 by another amino acid residue leads to 
activation of c-Src (Kmiecik and Shalloway, 1987). The inhibition of the csk gene 
activity also stimulates activity of PTK of the Src family (Imamoto and Soriano, 
1993). Phosphorylation at Tyr-416 in Src (or homologous amino acid residues in other 
tyrosine kinases) is necessary for complete activation of most kinases studied so far. 
In the absence of phosphorylation, the activating loop acquires different 
conformations, which often inhibit protein-protein interactions. In this active 
conformation the loop forms a part of the site recognized by the substrates (Xu et al., 
1997). 
 






Figure 6: The activation mechanism of Src tyrosine kinase. 
Reproduced from Roskoski (2004) and Xu et al. (1999). 
 
 
1.7 Src kinase and ion channels 
  
Both Src family and receptor tyrosine kinases are known to be potent 
modulators of ion channels (Levitan, 1994; Siegelbaum, 1994). Modulation by Fyn 
and other Src-family tyrosine kinases on potassium channels, calcium channels, 
sodium channels and glutamate receptors has been reported earlier. Studies show that 
potassium channel KV2.1 is inhibited by Fyn tyrosine phosphorylation (Sobko et al., 
1998; Tsai et al., 1999). Tyrosine phorsphorolated KV1.5 interacts with the SH3 
domain of Src kinase (Holmes et al., 1996a; Nitabach et al., 2001). KV1.2 currents are 
inhibited by tyrosine phosphorylation (Peretz et al., 2000; Wischmeyer et al., 1998). 
In 2003, Hou et al. showed that Src/Fyn binds and modulates voltage-gated calcium 
channels (Hou et al., 2003). Cellular plasticity, a form of plasticity that modifies the 
input–output relationships of the entire neuron, is mediated by modulation of voltage-
gated sodium, calcium, and potassium channels by tyrosine posphorylation/ 










1.7.1 Src tyrosine kinase and voltage-gated sodium channels 
 
Physiological and biochemical studies show that sodium channels are 
regulated by tyrosine kinase. Sodium channel studies have shown that the kinase 
activity enhances the intrinsic slow inactivation gating process, and thereby reduces 
the availability of channels (Cantrell and Catterall, 2001; Carr et al., 2003; Chen et al., 
2006). Tyrosine phosphorylation and dephosphorylation have also been implicated in 
rapid sodium channel modulation (Hilborn et al., 1998; Ratcliffe et al., 2000). 
Tyrosine phosphorylation of these sodium channels is associated with a 
hyperpolarizing shift in steady-state inactivation, resulting in fewer available channels 
for generating an action potential. Recent studies done with sodium channels show 
that Fyn kinase binds to the rat brain sodium channel NaV1.2, enhances fast 
inactivation, and mediates inhibition of sodium currents by brain-derived neurotrophic 
factor (BDNF), acting through the neurotrophin receptor tyrosine receptor kinase B 
(TrkB) (Ahn et al., 2007). The molecular mechanism underlying the fast inactivation 
on NaV1.2 with Fyn tyrosine kinase is also reported. Fyn kinase binds to a Src 
homology 3 (SH3)-binding motif in the second half of the intracellular loop 
connecting domains I and II (LDI–DII) of NaV1.2. Mutation of that SH3-binding motif 
prevents Fyn binding and Fyn enhancement of fast inactivation of sodium currents. 
Fast inactivation of the closely related NaV1.1 channel is not modulated by Fyn. These 
channels do not contain a SH3-binding motif in LDI–DII. 
In cardiac sodium channels, very few studies show that they behave oppositely from 
their neuronal counterparts. Hyperpolarizing shift is observed in the inactivation-
voltage relationship, when tyrosine kinase inhibitors are added to cardiac myocytes 
(Wang et al., 2003). This suggests that the phosphorylated form of the cardiac channel 
displays enhanced excitability. In 2005, Richard Horn‟s group (Ahern et al., 2005) 
expressed SCN5A clones (hH1) in HEK cells. They found that Fyn shifts the 
inactivation-voltage relationship towards more hyperpolarizing potentials and the 
kinase activity dead mutant of Fyn reversed the effect. 
 
 




1.7.2 Physiological relevance of cardiac sodium channels and Src family 
tyrosine kinase modulation 
 
Cardiac sodium channel NaV1.5 (Maier et al., 2002) and Src tyrosine kinase 
(Holmes et al., 1996b; Toyofuku et al., 2001) are accumulated at the adherens 
junctions. Adherens junctions are made up of protein complexes linking the cell 
membranes and cytoskeletal elements within and between cells. Adherens junctions 
are responsible for the electrical coupling between cardiac myocytes (Ahern et al., 
2005). Gap junctions in cardiac myocytes are reduced because of the c-Src-mediated 
tyrosine phosphorylation of Connexin-43. It also decreases the stability of Connexin-
43 at the cell surface as well as in the whole cell (Toyofuku et al., 2001). Non-
pathological stimulation of adrenergic ligands (Ma and Huang, 2002), angiotensin II 
(Sadoshima et al., 1995), epidermal growth factor (Wu et al., 2000) or insulin (Zhang 
and Hancox, 2003) are induced by tyrosine kinase activity in the heart.  
 
1.7.3 Modulation of sodium channel variants by Fyn tyrosine kinase 
 
In cardiac sodium channel variants, there is evidence which shows that sodium 
currents behave oppositely to their neuronal counterparts. In 2005, Ahern et al. 
showed that Fyn tyrosine kinase shifts the inactivation kinetics to more depolarizing 
potentials in HEK cells expressing NaV1.5 (hH1 clone). Later in 2007, Beacham et al. 
argued that the cardiac sodium channel does not have equivalent SH3 domain binding 
residues compared to the neuronal counterpart, so that the fast inactivation is shifted 
to more depolarizing potentials. Y1495 in the loop LDIII-DIV is required for 
phosphorylation, in turn leading to the shift in inactivation. Equivalent Y1495 in the 













Table 3: Different cardiac sodium channel variants 
International Human Genome Sequencing Consortium (IHGSC) sequence and 
reference sequence; hH1, hH1b and hH1c are previous cDNA clones of SCN5A; 
Accession No., GenBank nucleotide accession numbers, amino acid frequency (AAF), 
and variant name, name relative to SCN5A (defined herein as identical to IHGSC), 
AA No. indicates amino acid position number in the protein, using the full-length 
numbering consistent with the IHGSC databases. Population frequency indicates 
estimated percentage of channels in the study population. 
 
Common Name IHGSC hH1 hH1b hH1c AAF 
Accession No. AC137587 M77235 AF482988 AY148488 
AA. No.  558 H H R H 70% H 
559 T T T T 100% T 
618 L L I L 100% L 
1027 R Q R R 100% R 
1077 Q Q Δ Δ 65% Δ 


















The main aim of this project is to investigate the role of the Glutamate1077 
residue in the intracellular loop (LDII-III) connecting Domain II and III of the voltage-
gated cardiac sodium channel in modulation by Fyn tyrosine kinase. In particular I 
address the following questions: 
1. The role of Q1077 in LDII-III in the modulation of the sodium channel by Fyn 
tyrosine kinase? 
2. Can Q1077 mutation affect the modulation by Fyn? 
3. What is the potential SH3 binding motif in NaV1.5 which differs from NaV1.2 
in modulation by Fyn kinase? 
4. What are the potential residues involved in modulation of different sodium 
channel isoforms by Fyn kinase? 
5. What are the unique amino acid sequences in the loop LDII-III of cardiac 









3.1 Molecular Biology 
 
3.1.1 DNA clones 
 
Q1077Pre and Q1077Del clones in pcDNA3-N were kindly provided by Prof. 
Jonathan C Makielski, University of Wisconsin, Madison. Fyn tyrosine kinase active 
(∆Tyr 527) clone pCS2-c-FynCA and tyrosine kinase dead (K299M) clone pCS2-c-
Fyn
KD
 were gifts from Dr Richard Horn, Jefferson Medical College, USA. πH3-CD8 
was a gift from Dr. B. Seed, Harvard Medical School, Boston, MA, USA 
 
3.1.2 DNA amplification and isolation 
 
Subcloning Efficiency™ DH5α™ (Invitrogen®) competent E. coli cells were 
used to transform the gifted cDNAs. Transformation was performed according to the 
manufacturer‟s protocol. The transformed cells were plated on LB Ampicilline plates. 
Then the transformed clones were picked from the LB plates and grown in SOC 
medium overnight. The overnight culture was used to isolate cDNA. Isolation of 
cDNA from the overnight culture was done using QIAGEN
®
 mini and midiprep kits 
according to the manufacturer‟s protocol. Using Nanodrop spectrophotometer the 
concentration of the purified DNA from QIAGEN
®
 mini and midiprep was obtained. 
cDNA were verified using restriction enzyme digestion and run on an agarose gel 
electrophoresis. 




The components of the LB Ampicillin plates were: 
 10 g Tryptone Yeast Extract 
   5 g Yeast Extract  
 10 g NaCl  
 20 g Agar 
 1 l double distilled H2O and autoclaved 
10 ml of Ampicillin (concentration 100 mg/ml) was added and 7-10 ml were 
poured in each plate. 
 
The components of the SOC medium were: 
 5 g Yeast Extract 
 20 g Tryptone 
 0.5 g NaCl 
 1 l double distilled H2O and autoclaved 
10 ml filter-sterilized (0.2 µm filter) solution of 1M MgCl2, 1M MgSO4 and 2M 
glucose was added. 
 
3.1.3 Site-directed mutagenesis 
 
Site-directed mutagenesis was performed using Stratagene Quick Change Site-
Directed Mutagenesis Kit according to the manufacturer‟s protocol. Q1077Present 
(GenBank AC137587) NaV1.5 cDNA was used as the template for the mutation 
process. Both forward and reverse primers were designed using Stratagene primer 
design program. The forward primer and reverse primers for all the mutants are given 
in Table 4. Primers were ordered from Sigma
®














Table 4: Forward and reverse primers for Q1077 mutations. 
 
Oligo Name                Sequence 5' to 3' 
  
Q1077A Forward CCAGCAAGCAGGCGGAATCCCAGC 
Q1077A Reverse GCTGGGATTCCGCCTGCTTGCTGGAC 
  
Q1077K Forward GAGTCCAGCAAGCAGAAGGAATCCCAGCC 
Q1077K Reverse CAGGCTGGGATTCCTTCTGCTTGCTGGACTC 
  
Q1077P Forward GTCCAGCAAGCAGCCGGAATCCCAGCCTG 
Q1077P Reverse CAGGCTGGGATTCCGGCTGCTTGCTGGAC 
  
Q1077Y Forward GGAGTCCAGCAAGCAGTATGAATCCCAGCCTGTGT 
Q1077Y Reverse ACACAGGCTGGGATTCATACTGCTTGCTGGACTCC 
 
The reagents were added according to the manufacturer‟s instruction manual in 200 µl 
Polymerase chain reaction (PCR) tubes. Then the tubes were placed in the PCR 
machine, with programmed cycling parameters given below in Table 5.  
 
Table 5: PCR cycling parameters Quick Change Site-Directed Mutagenesis. 
 
Segment Cycle Temperature Time 
1 1 95ºC    2 minutes 
2 18 95ºC  20 seconds 
95ºC  10 seconds 
95ºC 6.1 minute 
3 1 95ºC    5 minutes 
 
The PCR product was then transformed into the XL10-Gold ultra-competent cells 
according to the transformation protocol provided by the manufacturer. The 
transformed cells were plated on LB Ampicillin plates for more than 16 hours. Then 




the transformed clones were picked from the LB plates and grown in SOC medium 
overnight. The overnight culture was used to isolate cDNA. Isolation of cDNA from 
the overnight culture was done using QIAGEN
®
 mini and midiprep kits according to 
the manufacturer‟s protocol. Using Nanodrop spectrophotometer from Thermo 
Scientific, the concentration of the purified DNA from QIAGEN
®
 mini and midiprep 
was obtained. The sequence of the DNA was verified using restriction enzyme 
digestion and sequencing. 
 
 




Human embryonic kidney tsA-201 cells with a passage number less than 25 
were used for the experiments. 
HEK293 stable cells encoding for Q1077Present (GenBank AC137587) and Q1077 
Deleted (GenBank AY148488) were obtained from Prof. Jonathan C. Makielski, 
University of Wisconsin, Madison. 
 
3.2.2 Cell culture media 
 
DMEM-F-12 (Dulbecco‟s modified Eagle‟s medium/nutrient mixture F12 
Ham) was purchased from Sigma-Aldrich GmbH for tsA-201cells. MEM (Modified 
Eagle‟s medium), MEM Sodium Pyruvate, L-Glutamine, Non-essential Amino Acids, 
and Geneticin were purchased from Sigma-Aldrich GmbH for stably transfected cells. 
Fetal calf serum (FCS) and Fetal bovine serum (FBS) was purchased from Sigma-




 10X: 2.00 g KCl, 2.0 g KH2PO4, 80.0 g 
NaCl, 27.07 g Na2PO4.2H2O, 1000 ml distilled H2O. Mixed to dissolve, this solution 
was diluted 1:10 with distilled H2O, sterile filtrated before use and stored at 4 °C. 





 1X. Mix to dissolve. This solution was sterile filtrated and stored at –20 




 1X before use. 
 




3.2.3 Sub-culturing cells 
 
3.2.3.1 Stably transfected cells 
 
Stably transfected cells were grown on tissue culture flasks until 70% 
confluent cells. Medium was aspirated from plates, then cells were washed with 2 ml 
1x PBS, twice. 2 ml trypsin (0.25% trypsin, 0.02% EDTA) was added and incubated 
for 2 min at 37°C. 3 ml of medium was added to quench and transferred to a 15 ml 
tube. The tube was centrifuged for 2 min at 1,000 RPM. After the medium was 
aspirated off the plates, 5 ml medium was added to resuspend the cells. 1/10 of the 
cell/media mixture was added to a new plate with fresh medium. The flask was placed 
in a 37°C incubator and checked every 2-3 days for growth. Cells for transfection 
were plated on Petri dishes (Falcon) at 30–50% confluence ∼16 h before transfection. 
For cryostorage the resuspended cells were added to a medium (without antibiotics) 
containing 10% FBS and 5% DMSO. 
 
Table 6: Medium composition for culturing stably transfected cells. 
 
Reagent Volume 
MEM 500 ml bottle 
MEM Sodium Pyruvate 5 ml 
L-Glutamine 5 ml 
MEM non-essential AA solution 5 ml 
FBS (Fetal Bovine Serum)  50 ml 
 
 
3.2.3.2 tsA Cells 
 
Human embryonic kidney tsA-201 cells were grown at 5% CO2 and 37 °C to 
70% confluence in Dulbecco‟s modified Eagle‟s/F-12 medium supplemented with 
10% fetal bovine serum (FBS). Cells were split using trypsin/ EDTA and plated on 
35-mm Petri dishes (Falcon) at 30–50% confluence ∼16 h before transfection. 
 






3.2.4.1 Transient transfection of stably transfected HEK cells 
 
Before transfection, the medium was replaced with fresh medium, and the 





with πH3-CD8 cDNA using the QIAGEN polyfect transfection reagents according to 
the manufacturer‟s protocol. Cells were incubated overnight at 37°C in 5% CO2. After 
12–16 h, the medium was replaced, and the cells were allowed to recover for 9–24 h 
before experiments. Anti-CD8-coated beads (Dynal, Oslo, Norway) were used to 
identify transfected cells (Jurman et al., 1994). 
. 
3.2.4.2 Transient transfection of mutant clones 
 
Sodium channels were transiently expressed for electrophysiological analysis 
by transfecting tsA-201 cells in 35 mm dishes with 1.2 µg of cDNA encoding the 
NaV1.5 (Genebank AC13758) α- subunit mutants Q1077A, Q1077P, Q1077Y, 
Q1077K and πH3-CD8 cDNAs with or without 0.1 µg of FynCA or FynKD cDNA, 
using the QIAGEN polyfect transfection reagents according to the manufacturer‟s 
protocol. Anti-CD8-coated beads (Dynal, Oslo, Norway) were used to identify 





3.3.1 Patch pipettes  
 
Patch pipettes were made in three stages: pipette pulling, heat polishing and 
filling. The patch pipettes were pulled from borosilicate glass 1.5mm O.D. X 0.86mm 
I.D. (Harvard Apparatus, UK) using a programmed Flaming/Brown micropipette 
puller (P-87, Sutter Instrument Company, CA, USA). The pipette tips were heat 
polished on a Micro-Forge model MF-79 (Narishige Scientific Instrument Lab., 
Tokyo, Japan). The pipette tip polishing was observed at 16 x 35 magnification using 




a compound microscope with a long distance objective (Leitz Biomed, Wetzlar, 
Germany). This procedure further reduced the tip opening to a final resistance of ≤ 5-
8 MΏ. The pipette solution was back filled using hypodermic needles of size 0.60 X 
60mm 23GX2-3/8” (Enosa, ROSE GmBh, Germany). The pipette solution must be 
filtered before using with a pore size equivalent to 0.2 mm in diameter (Sartorius, 
Göttingen, Germany). The pipette resistance was controlled before patch formation. 
Pipettes with a resistance lower than 1.5 MΏ were rejected and also pipettes with a 
resistance higher than 10 MΏ. Usually, the pipette resistance between 1.5-3.5 MΏ 
was used for whole cell patch clamp experiments.  
 
3.3.2 Patch clamp solutions  
 
Macroscopic INa was recorded using the whole cell patch-clamp technique.  
 
3.3.2.1 Stably transfected HEK cells  
 
The bath (extracellular) solution contained (in mM) 20 NaCl, 120 C5H14ClNO, 
4 KCl, 1.8 CaCl2, 0.75 MgCl2, and 5 HEPES (pH 7.4 with NaOH). The pipette 
solution contained (in mM) 120 CsF, 20 CsCl, 5 EGTA, and 5 HEPES (pH 7.4 set 
with CsOH).  
 
3.3.2.2 tsA-201 cells with Q1077 mutants 
 
The bath (extracellular) solution contained (in mM) 140 NaCl, 4 KCl, 1.8 
CaCl2, 0.75 MgCl2, and 5 HEPES (pH 7.4 with NaOH). The pipette solution 
contained (in mM) 120 CsF, 20 CsCl, 5 EGTA, and 5 HEPES (pH 7.4 set with 
CsOH).  
 
3.3.3 Experimental set-up 
 
The patch clamp set-up consisted of the microscope (Axiovert 100, Carl Zeiss, 
Germany), amplifier (Axopatch 200B, Axon Instruments, CA, USA), headstage (CV 
203BU Axon Instruments, CA, USA), pipette holder (HL-U, Axon Instruments, Inc., 




Foster City, Ca, USA), micromanipulator (Patchman, Eppendorf, Hamburg, 
Germany), computer, metal cage and vibration isolation table (Newport Corporation, 
Irvine, CA, USA). The silver wire was chlorinated every week before using as an 
electrode.  
Membrane currents were recorded with an Axopatch 200B amplifier (Axon 
Instruments). Data were acquired using pCLAMP 10.2. Peak INa was obtained after 
passive leak subtraction. Data were digitized at 100 kHz and were low pass filtered at 
10 kHz. Parameter fits were obtained using Origin 7.0. 
 
3.3.4 Pulse protocol 
 
Pulse protocol for activation curves 
Current was elicited by a clamp from a holding potential of -140 mV to 
various test pulses (-60, -55, -50, -45, -40, -35, -30, -25, -20, -15, -10, 0, +10, +20, 
+30, +40, +50, +60, +70 mV) for 24 ms. 10 s was given between each sweep. 
 
Pulse protocol for inactivation curves 
Current recordings were obtained when the cells were clamped from a holding 
potential of -140 mV to 100 ms prepulses at -130, -120, -110, -105, -100, -95, -90,  
-85, -80, -75, -70, -65, -60, -50, -40, -30, -20, -10, and 0 mV, followed by a 24 ms test 
pulse to 0 mV. 
 
3.3.5 Data acquisition and analysis 
 
For the study of peak current-voltage relationships, data were normalized to 
the peak INa in each data set. The current-voltage (I-V) curves were fitted according to 
the following modified Boltzmann function: GNa = [1 + exp (V1/2-V)/ kact]
-1
, where 
V1/2 and kact are the mid-point and the slope factor, respectively, and GNa = INa/(V-
Vrev) where Vrev is the reversal potential. For voltage dependence of “steady-state” 
inactivation, INa was obtained in response to a test depolarization to 0 mV from a 
holding potential of –150 mV, followed by a 1 sec conditioning step to the various 
conditioning potentials (Vc). In order to normalize the capacity transients a 0.2 ms 
step back to -150 mV was applied before a test depolarization. The voltage dependent 




availability from inactivation was determined by fitting the data to the Boltzmann 
function: INa= INa-max [1+ exp (Vc-V1/2)/kinact]
-1
, where V1/2 and kinact are the midpoint 
and the slope factor, respectively, and V is the membrane potential. 
 
3.4 Bioinformatics Analysis 
 
Sequences of all the sodium channel variants were obtained from NCBI 
protein database. Later the sequences were aligned using the CLUSTALX: Multiple 
sequence alignment program (Larkin et al., 2007; Thompson et al., 1994) with default 









Previous results published on the modulation of the sodium channel by Fyn 
show that active Fyn shifts the steady-state inactivation in NaV1.2 (Beacham et al., 
2007) and NaV1.5 (Ahern et al., 2005) without affecting the steady-state activation 
kinetics. Therefore, particular attention was payed on studies of the steady-state 
inactivation kinetics of cardiac sodium channel variants (Q1077 and ΔQ1077) in 
presence and absence of Fyn. 
 
 
4.1 Voltage-dependent kinetic parameters for Q1077 and ΔQ1077 
cardiac sodium channel variants 
 
Modulation of sodium current kinetics by Fyn tyrosine kinases on stably 
expressed Q1077 and ΔQ1077 variants in HEK-293 cells was investigated. Figure 7 
shows the original current traces obtained with Q1077 and ΔQ1077 variants. From the 
Figure it is evident that ΔQ1077 has an increased peak INa compared to the Q1077 
variant. 
 


















Figure 7: Original traces illustrating steady-state activation and steady-state 
inactivation of sodium channel currents of both (1) Q1077Present and 
(2) ΔQ1077. 
In both variants, (1) and (2), (a) represents the activation current elicited from a 
holding potential of -140 mV to various test pulses (-60, -55, -50, -45, -40, -35, -30, -
25, -20, -15, -10, 0, +10, +20, +30, +40, +50, +60, +70) for 24 ms. 10 s was given 
between each sweep. (b) In both (1) and (2) current recordings are shown, which were 
obtained when the cells where clamped from a holding potential of -140 mV to 100 
ms prepulses at -130, -120, -110, -105, -100, -95, -90, -85, -80, -75, -70, -65, -60, -50, 
-40, -30, -20, -10, and 0 mV, followed by a 24 ms test pulse to 0 mV. 
 
 
Table 7 shows the voltage-dependent kinetic parameters for both Q1077 and ΔQ1077 
variants. There was no significant difference in the activation kinetics among both the 
variants. However, the V1/2 steady-state inactivation of ΔQ1077 was observed at more 
depolarized potentials (-79.39 ± 0.38 mV) than that of the Q1077 variant (-88.21 ± 
0.31 mV) (p<0.001). The slope (Kinact) of the inactivation curve of ΔQ1077 (5.20 ± 
0.27 mV) also differs from that of Q1077 (6.55 ± 0.21 mV) (p<0.001). These results 
indicate that the glutamate residue (Q) at position 1077 plays a role in the steady-state 
inactivation of the cardiac sodium channel. As shown in Figure 7 and Table 7 the 




peak INa of ΔQ1077 (3.78 ± 0.11 nA) was larger than that of the Q1077Present variant 
(1.92 ± 0.10 nA) (p<0.001). The decay of INa at 0 mV, for the portion of the INa trace 
after 90% of peak, was fitted using double exponential decay function. The values 
obtained from the fit are also tabulated in Table 7. The results on the decay of INa 
indicate that the fast component of the time constant (τf) in ΔQ1077 (1.69 ± 0.14 ms) 
is significantly different (p<0.001) from that of the Q1077Present variant (0.79 ± 0.46 
ms) (Table 7, Figure 7). 
 
Table 7: Voltage-dependent kinetic parameters for Q1077 and ΔQ1077 cardiac 
sodium channel variants. 
Data are given as the means ± SEM, obtained from curve fitting to n experiments. 
Activation, inactivation, and decay were obtained according to the protocol described 
in the Materials and Methods section. For the decay of INa at 0 mV, the portion of the 
INa trace after decay to 90% of the peak current was fit to a sum of exponentials:  
INa (t) = Af X exp –t/τf + As X exp –t/τs + offset, where t is time, τf and τs represent the 
time constants of the fast and slow components, and Af and As are amplitudes of fast 
and slow components, respectively.  
* Significant difference (ANOVA) for Q1077 and ΔQ1077 stably transfected cells 
p<0.001 
 
 ΔQ1077 Q1077Present 
Inactivation 
V1/2, mV -79.39 ± 0.38* -88.21 ± 0.31 
Slope, mV    5.20 ± 0.27*    6.55 ± 0.21 
n 9 8 
Activation 
V1/2, mV -48.16 ± 0.20 -47.65 ± 0.29 
Slope, mV    3.44 ± 0.10    3.60 ± 0.10 
n 5 4 
Peak Current 
INa, nA 3.78 ± 0.11* 1.92 ± 0.10 
n 8 4 
Decay ( 0 mV) 
Af 0.87 ± 0.11 0.85 ± 0.03 
τf, ms   1.69 ± 0.14* 0.79 ± 0.46 
τs, ms 3.78 ± 0.15 4.09 ± 0.90 
n 7 5 




Figure 8 shows the Boltzmann fitted curves of both steady-state activation and 
inactivation of (A) Q1077 and (B) ΔQ1077 cells on the normalized INa and GNa 
obtained from the original traces using the inactivation and activation pulse protocol 
as described in Material and Methods.  
 









































Figure 8: Boltzmann fitted steady-state inactivation and activation curves of (A)   
 Q1077Present and (B) ΔQ1077 stably transfected cells. 
Boltzmann fitting, using the functions as described above, was done on the 
normalized values from original traces. 




4.2 Inactivation properties of ΔQ1077 and Q1077 with FynCA, FynKD 
and tyrosine kinase inhibitor PP2 
 
To test whether Fyn tyrosine kinase can differently modulate ΔQ1077 and 





The constitutively active mutant, Fyn
CA
 lacks its inhibitory carboxyl terminus (amino 
acids upstream of 525 were deleted), whereas the kinase dead mutant Fyn
KD
 has a 
single point mutation at position K299M (Ahern et al., 2005; Nitabach et al., 2001). 
Figure 9 shows the steady-state inactivation curves of the sodium current from stably 
expressed cells (ΔQ1077 and Q1077), either alone or transiently transfected with 
active Fyn
CA








 on Q1077Present caused a 16-mV depolarizing shift of the 
steady-state inactivation curve (Figure 9 and Table 9). The V½ inactivation of 
Q1077Present was -88.21 ± 0.31 mV (n=8) and the V½ inactivation of Q1077Present 
with Fyn
CA
 was shifted to -72.98 ± 0.06 mV (p<0.001, n=6). This result indicates that 
the shift in steady-state inactivation of Q1077Present in presence of Fyn
CA
 is similar 
to the hH1 cardiac sodium channel variant modulation by Fyn
CA
. In the hH1 cardiac 
sodium channel, Fyn
CA 
caused a 5-mV shift of the steady-state inactivation curve 
from a V½ of -94.9 ± 2.4 mV to -89.4 ± 0.9 mV (Ahern et al., 2005). To prove that 
this shift was due to Fyn, Q1077Present cells were transiently transfected with Fyn
KD
. 
The data were confirmed as no shift was observed with Fyn
KD
 (-87.13±0.29, n=4). 
Further evidence was obtained with the kinase inhibitor PP2. PP2 inhibited the Fyn 
action and reversed back the depolarizing shift from -72.98 ± 0.06 mV caused by 
Fyn
CA





 and Src tyrosine inhibitor PP2 show that the depolarizing 
shift was caused by Fyn tyrosine kinase. 
Our experiments with Fyn
CA
 on ΔQ1077 caused a 9-mV hyperpolarizing potential 
shift of the steady-state inactivation curve (Figure 9 and Table 9) from an average V½ 
of -79.39 ± 0.38 mV (n=9) for ΔQ1077 stably expressed cells to -88.51 ± 0.31 mV in 
the presence of Fyn
CA
 (n=5) (p < 0.001). The hyperpolarizing shift caused by Fyn
CA
 
was similar to that observed in the NaV1.2 channel, in which a 5-mV shift from -64.2 
± 0.42 mV to -70.1 ± 0.32 mV was caused by Fyn (Beacham et al., 2007). When the 




ΔQ1077 cells were transiently transfected with FynKD no shift of the steady-state 
inactivation curve was observed (n=6). This study confirms that the hyperpolarizing 
shift was caused by Fyn
CA
. To substantially confirm that the shift in the inactivation 
of ΔQ1077 was due to Fyn, the cells which were transfected with FynCA were treated 
with 1 µmol/L of the Src kinase inhibitor PP2. The kinase inhibitor PP2 inhibited the 
Fyn action and reversed back the Fyn
CA
-caused hyperpolarizing shift from -88.51 ± 
0.31 mV to -78.52 ± 0.14 mV.
 
This clearly confirms that the hyperpolarizing shift was 
caused by Fyn tyrosine kinase. 
No significant difference was seen in the peak INa and the decay of current in both 
Q1077Present and ΔQ1077 with and without FynCA (Table 9). However, from 
analysis of steady-state inactivation it was evident that Q1077Present and ΔQ1077 
cardiac sodium channels behave differently in the modulation by Fyn tyrosine kinase. 
 
 
Table 8: Kinetic parameters for Q1077 and ΔQ1077 cardiac sodium channel 




 ΔQ1077 ΔQ1077 + Fyn
CA
 Q1077Present Q1077 + Fyn
CA
 
Peak Current  
INa, nA 3.78 ± 0.11 3.97 ± 0.28 1.92 ± 0.10 1.71 ± 0.26 
n         8 3 4 4 
Decay ( 0 mV) 
Af 0.87 ± 0.11 0.84 ± 0.12 0.85 ± 0.03 0.89 ± 0.49 
τf, ms 1.69 ± 0.14 1.45 ± 0.21 0.79 ± 0.46 0.96 ± 0.38 
τs, ms 3.78 ± 0.15 4.13 ± 0.63 4.09 ± 0.90 4.62 ± 0.16 
n         7 3 5 4 
 
  




Table 9: Half-maximal inactivation of both Q1077 and ΔQ1077 with FynCA,   
 Fyn
KD
 and with Fyn
CA
 + PP2. 
Data are derived from fits of Boltzmann function to normalized inactivation curves 











    
Q1077Present -88.21 ± 0.31 5.55 ± 0.21 8 
Q1077Present + Fyn
CA
   -72.98 ± 0.06*   6.73 ± 0.35* 6 
Q1077Present + Fyn
KD
 -87.13 ± 0.29 5.18 ± 0.24 4 
Q1077Present + Fyn
CA
 + PP2 -88.41 ± 0.09 5.91 ± 0.63 3 
    
∆Q1077  -79.13 ± 0.38 5.76 ± 0.27 9 
∆Q1077 + FynCA   -88.21 ± 0.31*   7.63 ± 0.18* 5 
∆Q1077 + FynKD -80.61 ± 0.36 5.97 ± 0.28 6 
∆Q1077 + FynCA + PP2 -78.88 ± 0.14 6.28 ± 0.37 2 













Q1077 Present + Fyn
CA
Q1077 Present + Fyn
KD

















Figure 9A: Expression of catalytic active Fyn
CA
 alters steady state inactivation 
curves in stably expressed Q1077Present and ΔQ1077 cells. 
A. Steady-state inactivation properties of stably expressed Q1077Present cardiac 
sodium channel current with Fyn
CA
. Solid line in (A) with filled squares corresponds 
to the Boltzmann ﬁt of current recorded from stably expressed Q1077Present cells. 
The V1/2 of Q1077Present is -88.21 ± 0.31 mV. The Boltzmann ﬁt curve with open 
circles represents data obtained from stably expressed Q1077Present cells with Fyn
CA
. 
V1/2 of Q1077Present expressed with Fyn
CA
 is -72.98 ± 0.06 mV. When Q1077Present 
cells were expressed with Fyn
KD
, represented by filled up-pointing triangles, the V1/2 
is -87.13 ± 0.29 mV. To test the Src tyrosine kinase inhibitor action, the 
Q1077Present cells tranfected with Fyn
CA
 were incubated with the speciﬁc tyrosine 
kinase inhibitor PP2 (1 µmol/L) for 30 minutes before current recording. The curve 
with filled down-pointing triangles denotes the Boltzmann fit of Q1077Present in 
presence of Fyn
CA
 and the speciﬁc tyrosine kinase inhibitor PP2; the V1/2 is  
















Q1077 Deleted + Fyn
CA
Q1077 Deleted + Fyn
KD

















B. Similar inactivation curves for ΔQ1077 cells are shown as explained above for 
Q1077Present cells. Boltzmann ﬁt of stably expressed ΔQ1077 cells is denoted with 
filled squares. The V1/2 inactivation of ΔQ1077 is -79.39 ± 0.38 mV. The inactivation 
curve of stably expressed ΔQ1077 with FynCA is represented by open circles. V1/2 for 
ΔQ1077 expressed with FynCA is -80.76 ± 0.36 mV. The inactivation curve for 
ΔQ1077 cells expressed with FynKD is represented by filled up-pointing triangles; the 
V1/2 is -80.76 ± 0.36 mV. The Boltzmann fitted inactivation curve for the ΔQ1077 
cells in presence of Fyn
CA
 and PP2 is depicted with filled down-pointing triangles. 














4.3 Activation Properties of ΔQ1077 and Q1077 with FynCA 
 
To determine whether Fyn
CA
 can modulate the steady-state activation of 
ΔQ1077 and Q1077Present, the cells were transfected with FynCA, and the normalized 
conductance of ΔQ1077 and Q1077 with or without FynCA was analysed. The steady-
state activation of ΔQ1077 and Q1077Present in presence or absence of FynCA is 
shown in Figure 10 and Table 10.  
 




Data derived from fits of a Boltzmann function to normalized activation curves, 









    
Q1077  -48.91 ± 0.22 3.87 ± 0.13 5 
Q1077 + Fyn
CA
 -49.17 ± 0.23 4.05 ± 0.23 3 
    
∆Q1077  -47.65 ± 0.29 3.69 ± 0.10 4 
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Figure 10: Steady-state activation curves of stably expressed Q1077 and ΔQ1077 
cardiac sodium channels. 
Boltzmann functions fit to normalized conductance were determined from individual 
cells as described in Materials and Methods.   
 
 









 did not cause any shift of the activation curve. Similarly, in ΔQ1077 
Fyn
CA
 also did not alter the activation curve (Table 10). 
These data clearly show that activation kinetics of the two variants, Q1077Present and 
ΔQ1077, is not modulated by Fyn. These results were consistent with earlier 
published results on Fyn modulation of steady state activation of NaV1.2 and NaV1.5 
(hH1) sodium channels (Ahern et al., 2005; Beacham et al., 2007).   
 
 
4.4 Sequence alignment of sodium channel subunits of the 
intracellular loop LDII-DIII 
 
 To ascertain the uniqueness of cardiac sodium channel sequence, the amino 
acid sequences of all the nine sodium channel isoforms were aligned using the 
multiple sequence alignment CLUSTAL X program. The Pfam database is a large 
collection of protein families, each represented by multiple sequence alignments and 
hidden Markov models (Finn et al., 2010). According to pfam06512 database 
(Marchler-Bauer et al., 2011), amino acids of the cardiac sodium channel between 
positions 953-1214 form one of the sodium ion-transport associated regions of the 
channel. In the predicted cardiac sodium channel structure (George et al., 1992), 
amino acids from position 953 to 1214 also form the intracellular loop connecting the 
DII and DIII region (LDII-DIII) of the cardiac sodium channel. Since Q1077 is present 
in the intracellular loop connecting domains II and III, amino acid sequences of this 
loop of all the sodium channel isoforms were aligned and analysed (Figure 11). 
From Figure 11 it is evident that the Q1077 residue is located in the amino acid 
sequence 1075-KQQESQP-1081, which is unique in the cardiac sodium channel. In 
LDII-DIII the amino acid sequences 1047-GEQPGQGTPGDPEPVCVPIAVAE-1053 
and 1116-QQWKAEPQAPGCGETP-1132 are also unique among different sodium 
channel isoforms (Figure 11).  
 






Figure 11: Alignment of the intracellular loop of sodium channel subtypes 
connecting Domain II and III (LDII-DIII). 
Amino acid numbering of cardiac sodium channel and the proposed structure (George 
et al., 1992) forms the base of the alignment. Corresponding LDII-DIII residues of the 
other sodium channel subtypes were used for the alignment.  
Asterisks denote consensus amino acids, colons denote high similarity of amino acids, 
and dots denote less similarity among the aligned amino acids. No symbol denotes 
lack of similarity among amino acids.  




4.5 Kinetics of Q1077 cardiac sodium channel mutants 
 
To analyse the importance of Q1077 in the cardiac sodium channel, the amino 
acid glutamate was replaced with different amino acids using the Stratagene Quick 
Change Site-Directed Mutagenesis Kit with the Q1077Present cDNA as the template. 
The Q1077 was mutated to lysine (Q1077K), alanine (Q1077A), proline (Q1077P), 
and tyrosine (Q1077Y). The steady-state inactivation kinetics was obtained as 
described in the Materials and Methods section. 
 
Q1077A Q1077Y












Figure 12: Original traces illustrating steady-state inactivation of the transiently 
transfected mutants at position Q1077 in tsA-201 cells: 
(a) Q1077K, (b) Q1077P (c) Q1077A (d) Q1077Y. Current recordings are shown, 
which were obtained when the cells were clamped from a holding potential of -140 
mV to 100 ms prepulses at -150, - 140, -130, -120, -110, -105, -100, -95, -90, -85, -80, 
-75,-70,-65, -60, -50, -40, -30, -20, -10, and 0 mV, followed by a 24 ms test pulse to 0 
mV. 




From Figure 12 it is evident that the peak INa of Q1077P was smaller than that of the 
other counterparts. To obtain detailed inactivation kinetics, the original traces were 
fitted with Boltzmann functions as done for Q1077Present and ΔQ1077 (Table 11). 
 
Table 11: Kinetic parameters for all four mutants of the Q1077 cardiac sodium 
channel. 
§ (p<0.001) Significant difference (ANOVA) of the mutants relative to Q1077Present.  




As illustrated in Table 11 the steady-state inactivation of mutants Q1077A and 
Q1077K was shifted to more hyperpolarizing potentials. The V1/2 inactivation of 
Q1077K was -97.47 ± 0.23 mV (n=3) and for Q1077A it was -101.61 ± 0.30 mV 
(n=6), which was statistically different (p<0.001) from the Q1077Present variant  
(-88.21 ± 0.31 mV, n=8). In contrast, there was no statistically significant difference 
in the steady-state inactivation kinetics of Q1077P (-88.21 ± 0.47 mV, n=4) and 
Q1077Y (-90.43 ± 0.35 mV, n=4) compared to the Q1077Present variant (-88.21 ± 
0.3 mV, n=8). This indicates that the mutation at position 1077 with alanine and 
lysine (Q1077A and Q1077K) altered the V1/2 inactivation. The peak INa of Q1077P 
 Q1077K Q1077P Q1077A Q1077Y 
Inactivation 
V1/2, mV -97.47 ± 0.23*
§
 -88.21 ± 0.47 -101.61 ± 0.30*
§
 -90.43 ± 0.35 
Slope, mV    6.13 ± 0.22    7.16 ± 0.32      6.39 ± 0.25    6.49 ± 0.32 
n              3            4              6           4 
Peak Current  
INa, nA -3.59 ± 0.92 0.81 ± 0.09* -4.48 ± 0.87 -3.24 ± 0.51 
n 4 3 3 3 
Decay ( 0 mV) 
Af 0.94 ± 0.27 0.64 ± 0.26 0.69 ± 0.25 0.86 ± 0.43 
τf, ms 0.53 ± 0.76 0.76 ± 0.11 0.65 ± 0.24 0.78 ± 0.63 
τs, ms 2.84 ± 0.33 2.44 ± 0.44   5.45 ± 0.70* 2.13 ± 0.14 
n 3 4 3 3 




(0.81 ± 0.09 nA, n=3) was statistically different (p<0.001) from that of the other 
mutants Q1077K (-3.59 ± 0.92 nA, n=4), Q1077A (-4.48 ± 0.87 nA, n=3) and 
Q1077Y (-3.24 ± 0.51 nA, n=3). Thus, the mutation from glutamine at position 1077 
to proline significantly reduced the peak INa. For the decay of INa at 0 mV, the portion 
of the INa trace measured after 90% of peak was fit to a sum of exponentials and the 
parameters are listed in Table 11. The decay time constant of the slow component (τs) 
for Q1077A was significantly (p<0.001) different from that of the other 1077 mutants 
(Q1077K, Q1077P and Q1077Y).   
 
 










, the mutant 




 in tsA-201 cells. Original traces 
were obtained using the inactivation protocol as described in the Materials and 
Method section. The obtained traces were then analysed and fitted using Boltzmann 
function. The results were plotted (Figure 13) and tabulated (Table 12). The 
difference in the modulation by Fyn
CA
 among different Q1077 mutants is presented in 
the following sections. 
 





When the neutral amino acid glutamine at position Q1077 was replaced with 
the basic residue lysine (Q1077K), the inactivation was shifted to more 
hyperpolarizing potentials (-97.47 ± 0.23 mV, n=6). Cells co-transfected with Fyn
CA
 
produced a statistically significant (p<0.001) hyperpolarizing shift from -97.47 ± 0.23 
mV to -102.95 ± 0.43 mV (n=3). This result was similar to that of the NaV1.2 sodium 
channel modulation by Fyn and ∆Q1077 stably tranfected cell modulation by Fyn. 
Q1077K with Fyn
KD
 (V1/2: -97.63 ± 0.98 mV, n=3) did not produced any shift of the 
inactivation curve. This strongly emphasises that the modulation in inactivation was 
due to Fyn. 
 









The polar glutamine residue at position 1077 was replaced with the unpolar 
residue alanine (Q1077A). Q1077A also produced a hyperpolarizing shift, which was 
even larger (13.4 mV) compared to the other three mutants (Table 12). Cells co-
transfected with Fyn
CA
 produced a statistically significant hyperpolarizing shift from  
-101.61 ± 0.30 mV (n=6) to -118.02 ± 0.36 mV (n=3). When the cells were co-
transfected with Fyn
KD
 no statistically significant shift in the inactivation (V1/2:  
-105.33 ± 0.51 mV) was observed. The results obtained for inactivation of INa of 
Q1077A were in line with the Q1077K mutant, but the shift caused due to Q1077A 
mutant was larger (Table 12). 
 





The aliphatic glutamine residue at position 1077 in the cardiac sodium channel 
was replaced with the heterocyclic amino acid residue proline (Q1077P). The steady-
state inactivation of the Q1077P mutant (-88.21 ± 0.47 mV, n=6) was not shifted. 
When the Q1077P mutant was co-transfected with Fyn
CA
, a statistically significant 
(p<0.001) hyperpolarizing shift from -88.21 ± 0.47 mV to -97.71 ± 0.38 mV (n=4) 
was produced. The hyperpolarizing shift was not observed in the Q1077P mutant 
transfected with Fyn
KD
 (-88.85 ± 0.89 mV, n=4). This hyperpolarizing shift caused by 
the mutant Q1077P with Fyn
CA
 was less compared to the Q1077A mutant, but more 
pronounced than with the Q1077K mutant. 
 





The aromatic amino acid residue tyrosine was substituted instead of the 
aliphatic glutamine residue at position 1077 (Q1077Y). Similar to mutant Q1077P, 
the steady-state inactivation of Q1077Y was also not shifted (-90.43 ± 0.35 mV, n=4). 
When the Q1077Y mutant was co-transfected with Fyn
CA
, a statistically significant 




(p<0.001) hyperpolarizing shift from -90.43 ± 0.35 mV to -99.79 ± 0.18 mV (n=3) 
was observed. Such a hyperpolarizing shift was not seen when the cells were co-
transfected with Fyn
KD
 (-90.45 ± 0.32 mV, n=3). 
 
 














    
Q1077Y -90.43 ± 0.35 6.49 ± 0.32 4 
Q1077Y + Fyn
CA
   -99.79 ± 0.18*   7.98 ± 0.13* 3 
Q1077Y + Fyn
KD
 -90.45 ± 0.32 6.62 ± 0.59 3 
    
Q1077P -88.21 ± 0.47 7.16 ± 0.32 6 
Q1077P + Fyn
CA
   -97.71 ± 0.38* 7.41 ± 0.14 4 
Q1077P + Fyn
KD
 -88.85 ± 0.89 6.65 ± 0.53 4 
    
Q1077K -97.47 ± 0.23 6.13 ± 0.22 6 
Q1077K + Fyn
CA
 -102.95 ± 0.43*   8.96 ± 0.24* 3 
Q1077K + Fyn
KD
 -97.63 ± 0.98 6.82 ± 0.63 3 
    
Q1077A -101.61 ± 0.30 6.39 ± 0.25 6 
Q1077A + Fyn
CA
   -118.02 ± 0.36* 6.84 ± 0.17 3 
Q1077A + Fyn
KD
 -105.33 ± 0.51 5.73 ± 0.28 5 
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Q1077A
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Figure 13: Expression of catalytic active Fyn
CA
 alters steady-state inactivation  
 kinetics of Q1077 mutants. 
Boltzmann function fitted steady-state inactivation curves of four Q1077 mutants - 





shown. Solid lines with filled squares correspond to Boltzmann ﬁts of the respective 
transiently transfected mutant. Cells expressing both, Q1077 mutants and Fyn
CA
, are 
represented by open circles. Q1077 mutants expressed with Fyn
KD
 are represented by 
open triangles. Number of experiments is given in Table 12. 




Thus, the steady-state inactivation curves of all four different Q1077 mutants were 
shifted to more hyperpolarizing potentials when they were co-expressed with Fyn
CA
. 
This hyperpolarizing shift in inactivation is similar to the modulation of NaV1.2 and 
∆Q1077 cardiac sodium channels caused by Fyn tyrosine kinase.  
 
 
4.6.5 Correlation between the mutant amino acid properties and the 
shift in inactivation curves. 
 
There is a linear correlation (R
2 
= 0.99) when the hydrophobicity of an amino 
acid side chain is plotted against the difference in shifts of the inactivation curves in 
presence and absence of Fyn
CA
 (Figure 14).  
 
    




























Figure 14: Plot showing the linear relationship (R
2
 = 0.99) between the  
hydrophobicity of an amino acid and the difference in shift of the 































































































































































































Figure 15: Plot showing the linear relationship between different properties of 
amino acids and the difference in shift of the inactivation curves 
(a) average mass (R
2 
= 0.45), (b) isoelectric point (R
2 
= 0.45), (c) Van der Waals 
volume (R
2 
= 0.67), (d) molar mass (R
2 = 0.76), (e) dissociation constant (α-COOH) 
pK1 (R
2 = 0.33) and (f) dissociation constant (α-NH3) pK2 (R
2 
= 0.16) of an amino 
acid and the difference in shift of the inactivation curves (∆V = V1/2, Mutant - V1/2, Mutant + 
Fyn
CA
) is shown. 




Linear correlation graphs of different properties of the amino acids plotted against the 
difference in shift of the inactivation curves (∆V mV) show weak or no correlation 
(Figure 15). Only molar mass (R
2 
= 0.76) and the Van der Waals volume (Vw) (R
2 
= 
0.67) were weakly correlated, whereas the other parameters like average mass (R
2 
= 
0.45), isoelectric point (R
2 
= 0.45), dissociation constant pK1 (R
2 
= 0.33) and pK2 (R
2 









In this study, it is shown that the voltage-gated sodium channel variants are 
modulated differently by Fyn, which is a member of the large Src tyrosine kinase 
family. The effect of Fyn tyrosine kinase has been evaluated by shifts observed in the 
steady-state inactivation curves of the sodium channel variants. The evidence of this 
difference in the modulation by Fyn tyrosine kinase is further supported by mutating 
the glutamine residue (Q1077) in the intracellular loop (LDII-DIII) to four different 
residues (A, P, K and Y). The amino acid sequence of the intracellular loop (LDII-DIII) 
of all the sodium channel isoforms was analyzed and the uniqueness of the cardiac 
sodium channel to other sodium channel isoforms is documented. Lastly, a search for 
putative Src tyrosine kinase SH3 and SH2 binding motifs in the amino acid sequence 
of the cardiac sodium channel was performed. 
 
5.1 Splice variant specificity of Fyn modulation of cardiac sodium 
channels 
 
Our results indicate that Fyn regulates inactivation of different cardiac sodium 
channel variants differently. The Q1077Present variant shifted the inactivation curve 
to more depolarizing potentials (15 mV), while the ∆Q1077 variant shifted the 
inactivation curve to more hyperpolarizing potentials (9 mV). Studies on the hH1 
polymorphic cardiac sodium channel variant shifted the inactivation curve with Fyn to 
more depolarizing potentials (5 mV) (Ahern et al., 2005). The hH1 sodium channel 
variant is composed of 2016 amino acids, and it has a glutamine residue at position 




1027 compared to Q1077Present, which has an arginine residue at this position. 
∆Q1077 (Q1077del) is a splice variant of the Q1077Present variant where an 
additional glutamine is inserted at position 1077 by a 5′-extension of exon 18 by the 
trinucleotide CAG (Makielski et al., 2003). The peak INa of ∆Q1077 is larger than in 
hH1, and V1/2 inactivation appeared at more depolarized potentials (+5 mV) than in 
the hH1 variant. The activation curve is not shifted in both the ∆Q1077 and hH1 
variant (Makielski et al., 2003). This suggests that Q1077 and surrounding residues 
may play a role in the steady-state inactivation kinetics of the cardiac sodium channel.  
There is also evidence that the ∆Q1077 variant behaves differently in the background 
of cardiac mutations causing channelopathies. The loss of function mutation G1406R 
in the cardiac sodium channel, which causes Brugada syndrome, shows difference in 
the partial expression defect with ∆Q1077 and Q1077 in the background. These data 
suggest that there might be a partial trafficking defect, expression defect or gating 
abnormalities due to loss of function of the G1406R mutation (Tan et al., 2006). 
Therefore, intracellular trafficking might play an important role in the difference of 
modulation.  
The putative site for CK2 (casein kinase 2) phosphorylation is reported to be 
(S/T)XX(E/D) (Meggio and Pinna, 2003). This sequence -SKQE- is present in loop 
LDII-DIII in the ∆Q1077 variant of the NaV1.5 cardiac sodium channel at position 1074 
to 1077. Inserting a glutamine residue (Q1077Present) abolishes the putative 
phosphoacceptor site for CK2 (Kerr et al., 2004).  
There is also a study which reports that ∆Q1077 is present in 45% of the NaV1.5 
transcript in human hearts, and the Q1077Present variant transcript is present in 25% 
of the human hearts (Makielski et al., 2003). The hH1 cardiac sodium channel 
transcript (Accession No. M77235), on which modulation by Fyn was studied (Ahern 
et al., 2005), is not present (0%) in the human population (Makielski, 2006). Thus, 
based on these previously published data and our own results on the modulation of 
inactivation of ∆Q1077 and Q1077Present by Fyn, we speculate that the glutamine 
residue at position 1077 and the neighbouring residues in loop LDII-DIII could play a 
role in the difference of modulation of the cardiac sodium channel by Fyn. 
  




5.2 Mutational effects at position 1077  
 
Our results indicate that substitution of aliphatic glutamine at position 1077 to 
aromatic tyrosine or heterocyclic proline does not have any effect on inactivation 
kinetics, as it was similar to the Q1077Present variant. Whereas, when aliphatic and 
polar glutamine was mutated to aliphatic and hydrophobic alanine or to the polar and 
basic amino acid lysine there was a shift in V1/2 inactivation observed compared to 
Q1077Present. In the case of Q1077A, alanine is a hydrophobic residue and it is 
ambivalent; that means it can be inside or outside the protein accessible area. This 
could lead to different hydrophobic interactions between other nearby residues, in turn 
hindering the inactivation process. In Q1077K, lysine substitution shifted the V1/2 
inactivation to more hyperpolarizing potentials compared to the Q1077Present 
variant. The lysine residue has the ability to interact with the solvent readily, which 
might have played a role in shifting the inactivation curve to more hyperpolarizing 
potentials. Q1077P and Q1077Y, which are bulky residues, could hinder the folding 
of loop LDII-DIII which is the ion transport associated region. 
Our results on mutation at position 1077 revealed that all the amino acid mutations 
from glutamine to alanine, lysine, tyrosine and proline caused a shift of the respective 
inactivation curves to more hyperpolarizing potentials with Fyn as observed in 
∆Q1077 (Figure 9) and NaV1.2 (Beacham et al., 2007). However, there is different 
extent of the hyperpolarizing shift among different mutations. The mutation with 
alanine caused a very large hyperpolarizing shift by Fyn, and the least hyperpolarizing 
shift was produced by the positively charged residue lysine. There was also a strong 
linear correlation (R
2
=0.99) between the hydrophobicity of the mutated amino acids 
and the extent of the Fyn-caused hyperpolarizing shift. Highly hydrophobic residues 
are present in the SH2 domain of the Src tyrosine kinase, and in addition also the 
peptide binding site of SH3 is composed of a hydrophobic groove. When Q is present 
at position 1077 there might be hindrance to the hydrophobic interaction between the 
SH domains and the cardiac sodium channel. There is weak linear correlation 
observed with molar mass (R
2
=0.76) or the Van-der-Waals volume (Vw) (volume of 
the union of overlapping spheres) (R
2
=0.67), respectively, and the difference in the 
hyperpolarizing shifts caused by Fyn. Vw plays an important role in the packing and 
folding of a protein (Richards, 1977). Thus, from our mutational analysis we can 




conclude that hydrophobicity, and to a lesser extent, the Van-der-Waals volume (Vw) 
of the amino acids is vital in the different modulation of the sodium channel by Fyn.  
  
 
5.3 Uniqueness of cardiac sodium channel intracellular loop LDII-DIII 
 
From the performed sequence analysis it is obvious that the glutamine residue 
at position 1077 is unique among different sodium channel isoforms (Figure 11). 
There are three short unique amino acid sequences present in the cardiac sodium 
channel compared to other sodium channel isoforms. The glutamine at position 1077 
is present in one of these unique sequences of the cardiac sodium channel as shown in 
the Figure 11. Glutamine at position 1076 and 1077 is surrounded by the charged 
amino acids lysine at position 1075 and glutamic acid at position 1078. In turn, both 
of these charged amino acids are surrounded by the polar residue serine. Thus, the two 
glutamine residues are hidden in between the two polar serine residues, which might 
hinder the flexibility of the sodium channel. This serine residue has the ability to form 
a hydrogen bond with other polar residues. It has the property of either accepting or 
donating a hydrogen bond. So, an additional glutamine at position 1077 might hinder 
the flexibility of the loop LDII-DIII. This might play an anchoring role in facilitating the 
SH domains of the Src tyrosine kinase to bind to the cardiac sodium channel.  
Recent studies on MOG1 (multicopy suppressor of gsp1), which is present in the 
nucleus and the cytosol of cardiac cells (Marfatia et al., 2001), demonstrate that it 
plays an important role in the regulation of nuclear protein trafficking (Wu et al., 
2008). It showed that MOG1 is an important cofactor for optimal expression of 
NaV1.5 at the cell membrane. When MOG1 and NaV1.5 were co-expressed in 
HEK293 cells, there was only an increase in the peak INa with no change in the 
biophysical characteristics. The interaction site for MOG1 in NaV1.5 is the loop 
connecting domain II and domain III (LDII-DIII) (Abriel and Kass, 2005; Wu et al., 
2008). Ankyrins are intracellular proteins which target and stabilize the membrane 
proteins including ion channels, transporters, exchangers and cell adhesion molecules 
in various tissues (Cunha and Mohler, 2006). Ankyrin-G binds to the -VPIAXXSD- 
motif in loop LDII-DIII of the cardiac sodium channel (Abriel and Kass, 2005; Mohler et 
al., 2004). SCN5A mutation (pE1053K) in Brugada syndrome patients leads to 




disruption of the interaction between NaV1.5 and ankyrin-G (Mohler et al., 2004). 
Thus, these studies on different intracellular proteins, which modulate the sodium 
channel, reveal that LDII-DIII is an essential target. From our results on cardiac sodium 
channel variants, modulation by Fyn suggests that the protein-protein interaction site 
for the sodium channel and Fyn should be present in LDII-DIII. 
 
 
5.4 Possible binding sites for the SH2 domain in the cardiac sodium 
channel 
 
Our results on the possible SH3 domain binding, poly-proline motif show that 
there are five such motifs in loop LDII-DIII. As shown in Figure 15, the NaV1.2 does not 
contain any proline-rich motif in LDII-DIII. Thus, this loop LDII-DIII could play an 
important role in SH3 binding and modulation of the cardiac sodium channel by Fyn. 
In NaV1.2 the consensus sequence for the potential binding site of the Fyn SH2 
domain, after phosphorylation, is present in the N- and C-terminal (Beacham et al., 
2007). The sequence for the potential SH2 binding site in NaV1.2 is reported as 66-
YGDI-69 in the N-terminal, and 1893-YEPI-1896 in the C-terminal. In the cardiac 
sodium channel corresponding sites were analysed using the sequence alignment 
program. There, the C-terminal -YGDI- is replaced by 68-YGNP-, whereas the N-
terminal has a corresponding 1988-YEPI-1992 sequence (Beacham et al., 2007). 
Similarly, in the NaV1.2 channel there is a Y730 which is located in LDI-DII near the 
SH3 binding motif (-RVLPILP-), which is required for optimal regulation by Fyn 
(Beacham et al., 2007). This Y730 residue is conserved in all other sodium channel 
isoforms except the cardiac sodium channel. In the cardiac sodium channel the 
corresponding Y730 is replaced by N688 (asparagine). In NaV1.2, it was speculated 
that the SH2 motifs in the N- and C-terminal and the SH3 motif in LDI-DII play a role 
in maintaining a high local concentration of Fyn. But in the cardiac sodium channel 
there is only one SH2 binding motif in the C-terminal and several putative SH3 
binding motifs in LDII-DIII. Earlier studies show that the Fyn SH2 domain binds to the  
-pYQQI- motif of the target protein (Songyang et al., 1993). However, there are some 
other SH2 domains which bind to different patterns. The growth factor receptor-
bound protein 2 (Grb2) SH2 domain binds to the -pYXNX- motif of the target protein 




(Rahuel et al., 1996), whereas the SH2 domain of the growth factor phospholipase C-
γ1 (PLC-γ1) binds to hydrophobic residues that follow pTyr (Ji et al., 1999). Thus, 
Fyn could also bind to different SH2 motifs in the cardiac sodium channel other than 
the putative SH2 binding motif in NaV1.2. Putative SH2 binding motifs are situated in 
the C-terminal of the cardiac sodium channel, because there are motifs (1811-YDSV-
1814 and 1977-YSVL-1980) apart from the conserved -YEPI-, which have a 
hydrophobic residue at the pY+3 residue. The pY+3 residue is tightly bound to the 
hydrophobic pocket, and this pocket is critical for the peptide specificity (Brändén and 
Tooze, 1999). Thus, valine in the 1811-YDSV-1814 motif and leucine in the 1977-
YSVL-1980 motif might form a tight hydrophobic interaction with the hydrophobic 
pocket of the SH2 domain. Mutational studies on these motifs will give an insight 
view on the SH2 binding pockets of the cardiac sodium channel.  
 
 
5.5 Putative SH3 domain binding sites in sodium channels 
 
The SH3 domain consists of a five-stranded up-and-down antiparallel β sheet. 
The peptide binding site is made up of a hydrophobic groove (Brändén and Tooze, 
1999). The SH3 domain of the Src tyrosine kinase binds to the target peptides which 
have proline-rich motifs (Lim, 1996; Yu et al., 1994). When the peptide binds to the 
SH3 domain, proline-rich segments adopt a left-handed poly-proline type II helix with 
three amino acids per turn. There are three ridges in the poly-proline helix of which 
two contact the SH3 domain of the protein tyrosine kinase. The SH3 domain of the 
Src tyrosine kinase contains a group of acidic amino acids and less hydrophobic 
amino acid residues (Brändén and Tooze, 1999). All known SH3 target proteins carry 
a consensus sequence -PXXP-. When v-src is expressed with the human voltage gated 
potassium channel subtype (hKV1.5) (Holmes et al., 1996b), it is phosphorylated. It 
was found that hKV1.5 contains two SH3 binding motifs (RPLPPLP) between amino 
acid residues 65 and 82 of the channel protein (Holmes et al., 1996b; Tamkun et al., 
1991).  
In NaV1.2 the SH3 binding motif for Fyn is present in LDI-DII (Figure 17) (Beacham et 
al., 2007). Insertion of a glycine residue in this motif (-PTLP- to -PTGLP-) nullifies 
the modulation of NaV1.2 by Fyn (Beacham et al., 2007). In Figure 17, the other 




putative SH3 binding motifs are also shown; there is no proline-rich motif present in 
LDII-DIII, but two putative SH3 binding proline-rich motifs are present in the N-
terminal region. In the cardiac sodium channel there are five -PXXP- motifs in  
LDII-DIII. The cardiac sodium channel has one -PXXP- motif in the loop LDI-DII, which 
is different from that of NaV1.2. Two of the -PXXP- motifs in LDII-DIII of the cardiac 
sodium channel are present in the unique sequence found when aligned with other 
sodium channel isoforms (Figure 16). This suggests that the putative SH3 domain 
binding motif of the cardiac sodium channel is present in loop LDII-DIII. These studies 
reveal that the SH3 domain binding domain of the NaV1.2 and NaV1.5 is different. 
Thus, this could contribute to the difference observed in the modulation by Fyn 
tyrosine kinase. 
Cardiac sodium channel sequence analysis reveals five putative SH3 binding domains 
in loop LDII-DIII (Figure 16), but there is no proline-rich motif in LDII-DIII of the NaV1.2 
sodium channel (Figure 17). Whereas, for the NaV1.2 channel it is proven that there is 
one SH3 binding motif present in the LDI-DII. However, the same motif is not present 
in NaV1.5. Inserting a residue in the SH3 motif of NaV1.2 alters the modulation of 
inactivation kinetics by Fyn. According to suggested proline-rich motifs binding the 
SH3 domain of Src tyrosine kinases (Yu et al., 1994), in the cardiac sodium channel 
out of five putative motifs, the sequences 986-RQRPQKP-992, 1120-KAEPQAP-
1126 and 1008-PYSPPPP-1014 in LDII-DIII are most likely to form the SH3 binding 
site for Fyn kinase (Figure 16). The first two putative motifs have a charged amino 
acid residue (R and K) two residues (any amino acid) before the first proline of the 
proline-rich motif which is responsible for the SH3 domain binding groove (Brändén 
and Tooze, 1999; Yu et al., 1994). The third, above mentioned, proline rich motif 
contains four continuous proline residues making it an ideal candidate for SH3 
domain binding. Apart from the previously mentioned proline-rich motifs there are 
two other SH3 binding -PXXP- motifs present in LDII-DIII. The two proline-rich motifs 
in LDII-DIII are 1039-PGDPEP-1044 and 1086-PEAPP-1090; these can also form the 
SH3 domain binding motif, but it lacks the charged R/K residue, two residues before 
the first proline of the -PXXP- motif. But the 1086-PEAPP-1090 is in very close 
proximity to the glutamine residue at position1077. Hence, the consideration of this 
motif for SH3 binding should not be left out. Apart from LDII-DIII, there is one weak 
SH3 binding, proline-rich motif (PLAP) in loop LDI-DII (Figure 16). Insertion mutation 




or removing the entire motifs will give an insight view on the SH3 binding site of the 














MANFLLPRGT SSFRRFTRES LAAIEKRMAE KQARGSTTLQ ESREGLPEEE
APRPQLDLQA SKKLPDLYGN PPQELIGEPL EDLDPFYSTQ KTFIVLNKGK
TIFRFSATNA LYVLSPFHPI RRAAVKILVH SLFNMLIMCT ILTNCVFMAQ
HDPPPWTKYV EYTFTAIYTF ESLVKILARG FCLHAFTFLR DPWNWLDFSV
IIMAYTTEFV DLGNVSALRT FRVLRALKTI SVISGLKTIV GALIQSVKKL
ADVMVLTVFC LSVFALIGLQ LFMGNLRHKC VRNFTALNGT NGSVEADGLV
WESLDLYLSD PENYLLKNGT SDVLLCGNSS DAGTCPEGYR CLKAGENPDH
GYTSFDSFAW AFLALFRLMT QDCWERLYQQ TLRSAGKIYM IFFMLVIFLG
SFYLVNLILA VVAMAYEEQN QATIAETEEK EKRFQEAMEM LKKEHEALTI
RGVDTVSRSS LEMSPLAPVN SHERRSKRRK RMSSGTEECG EDRLPKSDSE
DGPRAMNHLS LTRGLSRTSM KPRSSRGSIF TFRRRDLGSE ADFADDENST
AGESESHHTS LLVPWPLRRT SAQGQPSPGT SAPGHALHGK KNSTVDCNGV
VSLLGAGDPE ATSPGSHLLR PVMLEHPPDT TTPSEEPGGP QMLTSQAPCV
DGFEEPGARQ RALSAVSVLT SALEELEESR HKCPPCWNRL AQRYLIWECC
PLWMSIKQGV KLVVMDPFTD LTITMCIVLN TLFMALEHYN MTSEFEEMLQ
VGNLVFTGIF TAEMTFKIIA LDPYYYFQQG WNIFDSIIVI LSLMELGLSR
MSNLSVLRSF RLLRVFKLAK SWPTLNTLIK IIGNSVGALG NLTLVLAIIV
FIFAVVGMQL FGKNYSELRD SDSGLLPRWH MMDFFHAFLI IFRILCGEWI
ETMWDCMEVS GQSLCLLVFL LVMVIGNLVV LNLFLALLLS SFSADNLTAP
DEDREMNNLQ LALARIQRGL RFVKRTTWDF CCGLLRQRPQ KPAALAAQGQ
LPSCIATPYS PPPPETEKVP PTRKETRFEE GEQPGQGTPG DPEPVCVPIA
VAESDTDDQE EDEENSLGTE EESSKQQESQ PVSGGPEAPP DSRTWSQVSA
TASSEAEASA SQADWRQQWK AEPQAPGCGE TPEDSCSEGS TADMTNTAEL
LEQIPDLGQD VKDPEDCFTE GCVRRCPCCA VDTTQAPGKV WWRLRKTCYH
IVEHSWFETF IIFMILLSSG ALAFEDIYLE ERKTIKVLLE YADKMFTYVF
VLEMLLKWVA YGFKKYFTNA WCWLDFLIVD VSLVSLVANT LGFAEMGPIK
SLRTLRALRP LRALSRFEGM RVVVNALVGA IPSIMNVLLV CLIFWLIFSI
MGVNLFAGKF GRCINQTEGD LPLNYTIVNN KSQCESLNLT GELYWTKVKV
NFDNVGAGYL ALLQVATFKG WMDIMYAAVD SRGYEEQPQW EYNLYMYIYF
VIFIIFGSFF TLNLFIGVII DNFNQQKKKL GGQDIFMTEE QKKYYNAMKK
LGSKKPQKPI PRPLNKYQGF IFDIVTKQAF DVTIMFLICL NMVTMMVETD
DQSPEKINIL AKINLLFVAI FTGECIVKLA ALRHYYFTNS WNIFDFVVVI
LSIVGTVLSD IIQKYFFSPT LFRVIRLARI GRILRLIRGA KGIRTLLFAL
MMSLPALFNI GLLLFLVMFI YSIFGMANFA YVKWEAGIDD MFNFQTFANS
MLCLFQITTS AGWDGLLSPI LNTGPPYCDP TLPNSNGSRG DCGSPAVGIL
FFTTYIIISF LIVVNMYIAI ILENFSVATE ESTEPLSEDD FDMFYEIWEK
FDPEATQFIE YSVLSDFADA LSEPLRIAKP NQISLINMDL PMVSGDRIHC
MDILFAFTKR VLGESGEMDA LKIQMEEKFM AANPSKISYE PITTTLRRKH
EEVSAMVIQR AFRRHLLQRS LKHASFLFRQ QAGSGLSEED APEREGLIAY
VMSENFSRPL GPPSSSSISS TSFPPSYDSV TRATSDNLQV RGSDYSHSED
LADFPPSPDR DRESIV
 
Figure 16: Amino acid sequence of the Q1077 (Accession Number AC137587) 
cardiac sodium channel. 
The cardiac sodium channel numbering and the proposed structure (George et al., 1992) 
forms the base of different structural parts. The membrane embedded parts and the 
extracellular loops of domains I-IV are not highlighted. The intracellular parts of the sodium 
channel are highlighted in grey. The unique sequences in LDII-DIII are highlighted in red. The 
possible SH3 domain binding motifs (proline-rich) are highlighted in yellow. The intracellular 
tyrosine residues are marked in green. 













































Figure 17: Amino acid sequence of the NaV1.2 (Accession Number 
NP_001035232) neuronal sodium channel. 
The membrane embedded parts and the extracellular loops of domains I-IV are not 
highlighted. The intracellular parts of the sodium channel are highlighted in grey. The 
SH3 binding site in NaV1.2 loop LDI-DII is highlighted in red. The other possible SH3 
domain binding motifs (proline-rich) are highlighted in yellow. The tyrosine residues 
are marked in green. 
 
 
5.6 Importance of the tyrosine residues in sodium channel for Fyn 
tyrosine kinase 
 
In both NaV1.5 and NaV1.2, the tyrosine residue in the inactivation loop is 
essential for the modulation of the sodium channel by Fyn (Ahern et al., 2005; 
Beacham et al., 2007). In the neuronal sodium channel isoform NaV1.2, tyrosine 
residues Y1497 and Y1498 in the inactivation loop (LDIII–DIV) play an important role 
in the regulation by Fyn, whereas in the cardiac sodium channel NaV1.5, tyrosine at 
position Y1495 in LDIII-DIV is the residue responsible for the modulation. When Y1495 
is substituted to phenylalanine (Y1495F), the shift caused by Fyn is abolished in 
cardiac sodium channel (hH1). Mutation in NaV1.2 tyrosine residue Y1498F annuls 




the effect of Fyn. Our analysis on LDIII-DIV of the sodium channel isoforms reveal that 
95% of the amino acids were conserved in LDIII-DIV. The tyrosine residue, which is 
present in LDIII-DIV, is conserved in all sodium channel isoforms (Fig. 14 and 15, 
Appendix alignment). It plays an important role in the modulation of sodium channels 
by Fyn. Although the tyrosine residue is conserved in the inactivation loop, Fyn 
modulates the sodium channel isoforms differently.  
NaV1.1 is not modulated by Fyn (Beacham et al., 2007), whereas in NaV1.2 Fyn shifts 
the inactivation curve to more hyperpolarizing potentials (Beacham et al., 2007). In 
hH1 (Ahern et al., 2005) and Q1077Present (Figure 9 and Table 9) cardiac sodium 
channel variants, Fyn shifts the inactivation curves to more depolarizing potentials. In 
the ∆Q1077 (Figure 9 and Table 9) cardiac sodium channel variant and the Q1077A, 
Q1077Y, Q1077P and Q1077K mutants, the inactivation curves are shifted to more 
hyperpolarizing potentials. Thus, although all sodium channels have a conserved 
tyrosine residue in LDIII-DIV, which is responsible for the modulation, different sodium 
channels are modulated differently by Fyn. 
In loop LDII-DIII, there are two tyrosine residues, one at the distal end and one 
embedded in the proline-rich motif -PYSPPPP-. In NaV1.2, there is Y730 in LDI-DII, 
which is in close proximity to the SH3 binding domain that is involved in the 
regulation of Fyn (Beacham et al., 2007). In the cardiac sodium channel five putative 
SH3 binding sites are present in LDII-DIII. The tyrosine residues at position 1008 and 
1118 in LDII-DIII could contribute to the regulation of Fyn tyrosine kinase. Y1008 is 
unique in NaV1.5 compared to other sodium channel isoforms. The distal end tyrosine 
residue Y1118 in LDII-DIII is conserved in NaV1.2, NaV1.7, NaV1.3 and cardiac sodium 
channel NaV1.5. Hence, these two tyrosine residues in LDII-DIII of the cardiac sodium 









Results from the thesis proclaim that Q1077Present and ∆Q1077 encoding for 
cardiac sodium channel (NaV1.5) variants are differently regulated by Fyn tyrosine 
kinase. In Q1077Present, Fyn shifted the inactivation curve to more depolarizing 
potentials, whereas in ∆Q1077 it was shifted to more hyperpolarizing potentials. 
Mutational analysis at position 1077 revealed the role of glutamine at this position, 
which is important for the modulation by Fyn. Fyn shifted the inactivation curves of 
all mutants (Q1077A, Q1077K, Q1077P and Q1077Y) to more hyperpolarizing 
potentials. Hydrophobicity of the substituted amino acid is one of the prominent 
factors in the extent of the shift. Sequence alignment showed that the region around 
LDII-DIII is unique and the glutamine residue at position 1077 is present in one of the 
unique segments of LDII-DIII. Results from this thesis speculate that the putative SH3 
binding site should be situated in LDII-DIII, and the SH2 binding site in the C-terminal. 
These data will be pertinent in understanding the role of Q1077 and its surrounding 
amino acids, which are present in the transport associated region (LDII-DIII). Results 
show that LDII-DIII of the cardiac sodium channel is pivotal in Fyn binding and 








AF   Atrial Fibrillation 
BrS    Brugada syndrome 
Cav   Voltage-gated calcium channel 
CK2   Casein Kinase 2 
CNS    Central Nervous System 
DI-DIV   Voltage-gated sodium channel domain (I-IV) 
DRG    Dorsal Root Ganglion 
GoF   Gain-of-function 
hNaV   Human voltage gated sodium channel 
INa   Sodium Current  
KV   Voltage gated potassium channel 
LB   Lysogeny broth 
LQT   Long QT syndrome 
LoF   Loss-of-function 
mRNA   Messenger ribonucleic acid  
Na
+
   Sodium ion 
NaV   Voltage gated sodium channel 
NaV1.5X   cardiac sodium channel splice variants 
PTK   Protein tyrosine kinase 
rNaV   Rat voltage gated sodium channel 
S1-S6   Trans-membrane helices (1-6) 
SA   Sinoatrial 
SCNXA   Voltage gated sodium channel (X- Subtype) 
SH2   Src Homology 2 
SH3   Src Homology 3 
SIDS   Sudden infant death syndrome 
SOC   Super optimal broth (modified) 
Src tyrosine kinase Sarcoma tyrosine kinase 
SSS   Sick Sinus Syndrome 
TTX   Tetrodotoxin 
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Voltage-gated sodium channels are very large membrane proteins. They are 
encoded by ten genes in mammals. Sodium channels are a crucial component of 
excitable tissues; hence, they are a target for various drugs and toxins. NaV1.5 is the 
cardiac voltage-gated sodium channel involved in the rapid depolarizing phase of the 
cardiac action potential. This isoform is also involved in the propagation of electrical 
impulses in the heart. Out of nine Nav1.5 splice variants, four of them were functional. 
The splice variant ∆Q1077 and Q1077Present variant of NaV1.5 are present in 45% 
and 25 % of human population, respectively. Cardiac sodium channels are modulated 
by different intracellular proteins. Tyrosine kinases are one of the potent intracellular 
modulators of ion channels. Fyn, a member of the Src tyrosine kinase family, 
modulates sodium channel isoforms distinctly.  
Results on the Q1077Present and the ΔQ1077 variants show different steady-state 
inactivation in presence of catalytic active Fyn
CA
. While the Q1077Present variant 
shifted the inactivation curve to more depolarizing potentials, the ΔQ1077 variant 
shifted the inactivation curve to more hyperpolarizing potentials, similar to neuronal 
sodium channel NaV1.2. The Fyn-induced shift in inactivation of Q1077Present was 
similar to the modulation observed in the hH1 polymorphic cardiac sodium channel 
variant with Fyn. The Src tyrosine kinase inhibitor PP2 reversed back the shifts 
caused by Fyn
CA
 in both Q1077Present and ΔQ1077 cardiac sodium channel variants. 
Moreover, the kinase dead mutant Fyn
KD
 did not shift both the ΔQ1077 and 
Q1077Present inactivation curves. The activation curves of both Q1077Present and 
ΔQ1077 were not affected by active Fyn. Sequence analysis of all the sodium channel 
isoforms reveal that the Q1077glutamine is present in one the three unique sequences 
in the intracellular loop connecting the domain DII and DIII, which forms the „sodium 
ion transport associated‟ region. Point mutation at position 1077 from glutamine to 
alanine, lysine, tyrosine and proline shifted the inactivation curves to more 
hyperpolarizing potentials with Fyn
CA
. Linear correlation was observed between the 




hyperpolarizing shift caused by Fyn
CA
 and the hydrophobicity of the amino acids‟ 
side chains. Putative SH2 and SH3 binding sites for Fyn in the cardiac sodium 
channel were also determined. Five unique proline-rich motifs were identified, which 
are potential SH3 binding sites for Fyn in the cardiac sodium channel. Putative SH2 
binding motifs for Fyn were found in the C-terminal of Nav1.5.  
These data will be pertinent in understanding the role of Q1077 and its surrounding 
amino acids. The intracellular loop LDII-DIII, which is distinct in cardiac sodium 
channels from other sodium channel isoforms, forms one of the „sodium ion transport 
associated‟ regions. Thus, LDII-DIII plays a pivotal role in regulating cardiac sodium 
channel binding to various intracellular signaling molecules. 







Spannungabhängige Natriumkanäle sind sehr große Membranproteine. In 
Säugetieren werden sie von zehn Genen kodiert. Natriumkanäle spielen eine wichtige 
Rolle in erregbaren Zellen und sie sind deshalb ein wichtiger Angriffspunkt für 
Arzneistoffe und Toxine. NaV1.5 ist der spannungsabhängige Natriumkanal im 
Herzen, wo er für die rasche Depolarisationsphase im Aktionspotential verantwortlich 
ist und auch an der Reizweiterleitung beteiligt ist. Von den neun Spleißvarianten von 
NaV1.5 sind vier funktionell. Die Spleißvariante ΔQ1077 und die Q1077Present 
Variante des kardialen Natriumkanals sind in 45% bzw. 25% der Bevölkerung 
anzutreffen. Kardiale Natriumkanäle werden durch unterschiedliche intrazelluläre 
Proteine moduliert. Tyrosinkinasen sind eine der potenten Modulatoren verschiedener 
Ionenkanäle. Fyn, das zur Src Tyrosinkinase-Familie gehört, moduliert verschiedene 
Natriumkanal-Isoformen auf unterschiedliche Weise. Die mit den Q1077Present und 
ΔQ1077 Varianten erhaltenen Ergebnisse zeigten unterschiedliche Inaktivierung in 
Gegenwart katalytisch aktiver Fyn
CA
. Während die Q1077Present Variante die 
Inaktivierungskurve in die depolarisierende Richtung verschob, trat die halbmaximale 
Inaktivierung bei ΔQ1077 bei negativeren Potentialen auf, ähnlich wie beim 
neuronalen Natriumkanal NaV1.2. Die durch Fyn
CA
 bedingte Verschiebung der 
Inaktivierungskurve in der Q1077Present Variante war vergleichbar mit der durch 
Fyn
CA
 hervorgerufenen Modulation in der hH1 polymorphen kardialen Natriumkanal-
Variante. Mit der Kinase-toten Mutante Fyn
KD
 kam es weder bei ΔQ1077 noch bei 
Q1077Present zu einer Verschiebung der Inaktivierungskurven. Weiters konnte in 
beiden Varianten die durch Fyn
CA
 bedingte Verschiebung der Inaktivierungskurven 
durch den Src Tyrosinkinase-Hemmer PP2 aufgehoben werden. Die 
Aktivierungkurven beider Varianten, Q1077Present und ΔQ1077, wurden durch 
Fyn
CA
 nicht beeinflusst. Eine Sequenzanalyse aller Natriumkanal-Isoformen zeigte, 
dass Glutamin in Position 1077 in einer der drei für NaV1.5 einzigartigen Sequenzen 
in der intrazellulären Schleife liegt, die die Domänen DII und DIII verbindet und die 
"Natriumionentransport-assoziierte" Region bildet. Eine Punktmutation in Position 
1077 von Glutamin zu Alanin, Lysin, Tyrosin oder Prolin verschob die 
Inaktivierungskurven in Gegenwart von Fyn
CA
 zu negativeren Potentialen. Es konnte 




eine lineare Korrelation zwischen dem Ausmaß der Verschiebung der 
Inaktivierungskurven durch Fyn
CA
 und der hydrophoben Eigenschaft der 
Aminosäuren-Seitenketten beobachtet werden. Mögliche SH2 und SH3 
Bindungsstellen für Fyn im kardialen Natriumkanal wurden ebenfalls identifiziert. 
Fünf spezifische, prolinreiche Motive, die als SH3 Bindungsstelle für Fyn im 
kardialen Natriumkanal fungieren könnten, wurden aufgefunden. Mögliche SH2 
Bindungsmotive für Fyn wurden im C-Terminus von NaV1.5 identifiziert. 
Diese Daten tragen zum Verständnis der Rolle des Q1077 und den angrenzenden 
Aminosäuren bei. Die intrazelluläre Schleife LDII-DIII des kardialen Natriumkanals, die 
sich wesentlich von der anderer Natriumkanal-Isoformen unterscheidet, bildet eine 
der "Natriumionentransport-assoziierten" Regionen. Deshalb spielt LDII-DIII eine 
wichtige Rolle bei der Bindung intrazellulärer Signalmoleküle an den Natriumkanal.  







Nav1.1          ---MEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPD----KKDDDENGPKPNS 
Nav1.8          ---MEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPD----KKDDDENGPKPNS 
Nav1.9          ---MEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPD----KKDDDENGPKPNS 
Nav1.2          ---MAQSVLVPPGPDSFRFFTRESLAAIEQRIAEEKAKRPKQER---KDEDDENGPKPNS 
Nav1.3          ---MAQALLVPPGPESFRLFTRESLAAIEKRAAEEKAKKPKKE----QDNDDENKPKPNS 
Nav1.7          -----MAMLPPPGPQSFVHFTKQSLALIEQRIAERKSKEPKEE----KKDDDEEAPKPSS 
Nav1.6          ---MAARLLAPPGPDSFKPFTPESLANIERRIAESKLKKPPKADGSHREDDEDSKPKPNS 
Nav1.4          MARPSLCTLVPLGPECLRPFTRESLAAIEQRAVEEEARLQRNK----QMEIEEPERKPRS 
Nav1.5          ----MANFLLPRGTSSFRRFTRESLAAIEKRMAEKQARGSTTLQESREGLPEEEAPRPQL 
                        * * *...:  ** :*** **:* .* : :         .   ::   :*   
 
Nav1.1          DLEAGKNLPFIYGDIPPEMVSEPLEDLDPYYINKKTFIVLNKGKAIFRFSATSALYILTP 
Nav1.8          DLEAGKNLPFIYGDIPPEMVSEPLEDLDPYYINKKTFIVLNKGKAIFRFSATSALYILTP 
Nav1.9          DLEAGKNLPFIYGDIPPEMVSEPLEDLDPYYINKKTFIVLNKGKAIFRFSATSALYILTP 
Nav1.2          DLEAGKSLPFIYGDIPPEMVSVPLEDLDPYYINKKTFIVLNKGKAISRFSATPALYILTP 
Nav1.3          DLEAGKNLPFIYGDIPPEMVSEPLEDLDPYYINKKTFIVMNKGKAIFRFSATSALYILTP 
Nav1.7          DLEAGKQLPFIYGDIPPGMVSEPLEDLDPYYADKKTFIVLNKGKTIFRFNATPALYMLSP 
Nav1.6          DLEAGKSLPFIYGDIPQGLVAVPLEDFDPYYLTQKTFVVLNRGKTLFRFSATPALYILSP 
Nav1.4          DLEAGKNLPMIYGDPPPEVIGIPLEDLDPYYSNKKTFIVLNKGKAIFRFSATPALYLLSP 
Nav1.5          DLQASKKLPDLYGNPPQELIGEPLEDLDPFYSTQKTFIVLNKGKTIFRFSATNALYVLSP 
                **:*.*.** :**: *  ::. ****:**:*  :***:*:*:**:: **.** ***:*:* 
 
Nav1.1          FNPLRKIAIKILVHSLFSMLIMCTILTNCVFMTMSNPPDWTKNVEYTFTGIYTFESLIKI 
Nav1.8          FNPLRKIAIKILVHSLFSMLIMCTILTNCVFMTMSNPPDWTKNVEYTFTGIYTFESLIKI 
Nav1.9          FNPLRKIAIKILVHSLFSMLIMCTILTNCVFMTMSNPPDWTKNVEYTFTGIYTFESLIKI 
Nav1.2          FNPIRKLAIKILVHSLFNMLIMCTILTNCVFMTMSNPPDWTKNVEYTFTGIYTFESLIKI 
Nav1.3          LNPVRKIAIKILVHSLFSMLIMCTILTNCVFMTLSNPPDWTKNVEYTFTGIYTFESLIKI 
Nav1.7          FSPLRRISIKILVHSLFSMLIMCTILTNCIFMTMNNPPDWTKNVEYTFTGIYTFESLVKI 
Nav1.6          FNLIRRIAIKILIHSVFSMIIMCTILTNCVFMTFSNPPDWSKNVEYTFTGIYTFESLVKI 
Nav1.4          FSVVRRGAIKVLIHALFSMFIMITILTNCVFMTMSDPPPWSKNVEYTFTGIYTFESLIKI 
Nav1.5          FHPIRRAAVKILVHSLFNMLIMCTILTNCVFMAQHDPPPWTKYVEYTFTAIYTFESLVKI 
                :  :*: ::*:*:*::*.*:** ******:**:  :** *:* ******.*******:** 
 
Nav1.1          IARGFCLEDFTFLRDPWNWLDFTVITFAYVTEFVDLGNVSALRTFRVLRALKTISVIPGL 
Nav1.8          IARGFCLEDFTFLRDPWNWLDFTVITFAYVTEFVDLGNVSALRTFRVLRALKTISVIPGL 
Nav1.9          IARGFCLEDFTFLRDPWNWLDFTVITFAYVTEFVDLGNVSALRTFRVLRALKTISVIPGL 
Nav1.2          LARGFCLEDFTFLRDPWNWLDFTVITFAYVTEFVDLGNVSALRTFRVLRALKTISVIPGL 
Nav1.3          LARGFCLEDFTFLRDPWNWLDFSVIVMAYVTEFVDLGNVSALRTFRVLRALKTISVIPGL 
Nav1.7          LARGFCVGEFTFLRDPWNWLDFVVIVFAYLTEFVNLGNVSALRTFRVLRALKTISVIPGL 
Nav1.6          IARGFCIDGFTFLRDPWNWLDFSVIMMAYITEFVNLGNVSALRTFRVLRALKTISVIPGL 
Nav1.4          LARGFCVDDFTFLRDPWNWLDFSVIMMAYLTEFVDLGNISALRTFRVLRALKTITVIPGL 
Nav1.5          LARGFCLHAFTFLRDPWNWLDFSVIIMAYTTEFVDLGNVSALRTFRVLRALKTISVISGL 
                :*****:  ************* ** :** ****:***:***************:**.** 
 
Nav1.1          KTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCIQWPP----------T 
Nav1.8          KTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCIQWPP----------T 
Nav1.9          KTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCIQWPP----------T 
Nav1.2          KTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCLQWPP----------D 
Nav1.3          KTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCLQWPP----------S 
Nav1.7          KTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLKHKCFRN------------- 
Nav1.6          KTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCVVWP------------ 
Nav1.4          KTIVGALIQSVKKLSDVMILTVFCLSVFALVGLQLFMGNLRQKCVRWPPPFNDTNTTWYS 
Nav1.5          KTIVGALIQSVKKLADVMVLTVFCLSVFALIGLQLFMGNLRHKCVRNFT----------- 












Nav1.1          NASLEEHSIEKN-ITVNYNGTLINETVF----------EFDWKSYIQDSRYHYFLEGFLD 
Nav1.8          NASLEEHSIEKN-ITVNYNGTLINETVF----------EFDWKSYIQDSRYHYFLEGFLD 
Nav1.9          NASLEEHSIEKN-ITVNYNGTLINETVF----------EFDWKSYIQDSRYHYFLEGFLD 
Nav1.2          NSSFEINITSFFNNSLDGNGTTFNRTVS----------IFNWDEYIEDKSHFYFLEGQND 
Nav1.3          DSAFETNTTSYFNGTMDSNGTFVNVTMS----------TFNWKDYIGDDSHFYVLDGQKD 
Nav1.7          --SLENNETLES---------IMNTLES----------EEDFR------KYFYYLEGSKD 
Nav1.6          ---------------INFNESYLENGTK----------GFDWEEYINNKTNFYTVPGMLE 
Nav1.4          NDTWYGNDTWYGNEMWYGNDSWYANDTWNSHASWATNDTFDWDAYISDEGNFYFLEGSND 
Nav1.5          -------------ALNGTNGSVEADGLV----------WESLDLYLSDPENYLLKNGTSD 
                                                        .          .    *  : 
 
Nav1.1          ALLCGNSSDAGQCPEGYMCVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDFWENLYQLTL 
Nav1.8          ALLCGNSSDAGQCPEGYMCVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDFWENLYQLTL 
Nav1.9          ALLCGNSSDAGQCPEGYMCVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDFWENLYQLTL 
Nav1.2          ALLCGNSSDAGQCPEGYICVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDFWENLYQLTL 
Nav1.3          PLLCGNGSDAGQCPEGYICVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDYWENLYQLTL 
Nav1.7          ALLCGFSTDSGQCPEGYTCVKIGRNPDYGYTSFDTFSWAFLALFRLMTQDYWENLYQQTL 
Nav1.6          PLLCGNSSDAGQCPEGYQCMKAGRNPNYGYTSFDTFSWAFLALFRLMTQDYWENLYQLTL 
Nav1.4          ALLCGNSSDAGHCPEGYECIKTGRNPNYGYTSYDTFSWAFLALFRLMTQDYWENLFQLTL 
Nav1.5          VLLCGNSSDAGTCPEGYRCLKAGENPDHGYTSFDSFAWAFLALFRLMTQDCWERLYQQTL 
                 **** .:*:* ***** *:* *.**::****:*:*:****:******** **.*:* ** 
 
Nav1.1          RAAGKTYMIFFVLVIFLGSFYLINLILAVVAMAYEEQNQATLEEAEQKEAEFQQMIEQLK 
Nav1.8          RAAGKTYMIFFVLVIFLGSFYLINLILAVVAMAYEEQNQATLEEAEQKEAEFQQMIEQLK 
Nav1.9          RAAGKTYMIFFVLVIFLGSFYLINLILAVVAMAYEEQNQATLEEAEQKEAEFQQMIEQLK 
Nav1.2          RAAGKTYMIFFVLVIFLGSFYLINLILAVVAMAYEEQNQATLEEAEQKEAEFQQMLEQLK 
Nav1.3          RAAGKTYMIFFVLVIFLGSFYLVNLILAVVAMAYEEQNQATLEEAEQKEAEFQQMLEQLK 
Nav1.7          RAAGKTYMIFFVVVIFLGSFYLINLILAVVAMAYEEQNQANIEEAKQKELEFQQMLDRLK 
Nav1.6          RAAGKTYMIFFVLVIFVGSFYLVNLILAVVAMAYEEQNQATLEEAEQKEAEFKAMLEQLK 
Nav1.4          RAAGKTYMIFFVVIIFLGSFYLINLILAVVAMAYAEQNEATLAEDKEKEEEFQQMLEKFK 
Nav1.5          RSAGKIYMIFFMLVIFLGSFYLVNLILAVVAMAYEEQNQATIAETEEKEKRFQEAMEMLK 
                *:*** *****:::**:*****:*********** ***:*.: * ::** .*:  :: :* 
 
Nav1.1          KQQEAAQQAATAT----ASEHSREPSA--AGRLSDSSSEASKLSSKSAKERRNRRKKRKQ 
Nav1.8          KQQEAAQQAATAT----ASEHSREPSA--AGRLSDSSSEASKLSSKSAKERRNRRKKRKQ 
Nav1.9          KQQEAAQQAATAT----ASEHSREPSA--AGRLSDSSSEASKLSSKSAKERRNRRKKRKQ 
Nav1.2          KQQEEAQAAAAAASA--ESRDFSGAGG--IGVFSESSSVASKLSSKSEKELKNRRKKKKQ 
Nav1.3          KQQEEAQAVAAAS-A--ASRDFSGIGG--LGELLESSSEASKLSSKSAKEWRNRRKKRRQ 
Nav1.7          KEQEEAEAIAAAA----AEYTSIRRSR--IMGLSESSSETSKLSSKSAKERRNRRKKKNQ 
Nav1.6          KQQEEAQAAAMATSAGTVSEDAIEEEGEEGGGSPRSSSEISKLSSKSAKERRNRRKKRKQ 
Nav1.4          KHQEELEKAKAAQ----------------------------------------------- 
Nav1.5          KEHEALTIRGVDT-------------------VSRSSLEMSPLAPVNSHERRSKRRKR-- 
                *.:*                                                         
 
Nav1.1          KEQSGGEEKDEDE-FQKSESEDSIRRKGFRFSIEGNRLTYEKRYSSPHQSLLSIRGSLFS 
Nav1.8          KEQSGGEEKDEDE-FQKSESEDSIRRKGFRFSIEGNRLTYEKRYSSPHQSLLSIRGSLFS 
Nav1.9          KEQSGGEEKDEDE-FQKSESEDSIRRKGFRFSIEGNRLTYEKRYSSPHQSLLSIRGSLFS 
Nav1.2          KEQSGEEEKNDR--VRKSESEDSIRRKGFRFSLEGSRLTYEKRFSSPHQSLLSIRGSLFS 
Nav1.3          REHLEGNNKGERDSFPKSESEDSVKRSSFLFSMDGNRLTSDKKFCSPHQSLLSIRGSLFS 
Nav1.7          KKLSSGEEKGDAEKLSKSESEDSIRRKSFHLGVEGHRRAHEKRLSTPNQSPLSIRGSLFS 
Nav1.6          KELSEGEEKGDPEKVFKSESEDGMRRKAFRLPD--NRIG--RKFSIMNQSLLSIPGSPFL 
Nav1.4          -ALEGGEADGDP-----------------------------------------------A 
Nav1.5          --MSSGTEECGEDRLPKSDSEDGPR-------------------AMNHLSLTRGLSRTSM 
                        .                                                    
 
Nav1.1          PRRNSRTSLFSFRG--RAKDVGSENDFADDEHSTFEDNESRRDSLFVPRRHGERRNSNL- 
Nav1.8          PRRNSRTSLFSFRG--RAKDVGSENDFADDEHSTFEDNESRRDSLFVPRRHGERRNSNL- 
Nav1.9          PRRNSRTSLFSFRG--RAKDVGSENDFADDEHSTFEDNESRRDSLFVPRRHGERRNSNL- 
Nav1.2          PRRNSRASLFSFRG--RAKDIGSENDFADDEHSTFEDNDSRRDSLFVPHRHGERRHSNV- 
Nav1.3          PRRNSKTSIFSFRG--RAKDVGSENDFADDEHSTFEDSESRRDSLFVPHRHGERRNS--- 
Nav1.7          ARRSSRTSLFSFKG--RGRDIGSETEFADDEHSIFGDNESRRGSLFVPHRPQERRSSNI- 
Nav1.6          SRHNSKSSIFSFRGPGRFRDPGSENEFADDEHSTVEESEGRRDSLFIPIRARERRSSYSG 
Nav1.4          HGKDCNGSLDTSQG---------------------------------------------- 
Nav1.5          KPRSSRGSIFTFRR----RDLGSEADFADDENSTAGESESHHTSLLVPWPLRRTSAQGQ- 
                  :... *: : :                                                




Nav1.1          ----SQTSRSSRMLAVFPANGKMHSTVDCNGVVSLVGGPSVPTSPVGQLLP--------- 
Nav1.8          ----SQTSRSSRMLAVFPANGKMHSTVDCNGVVSLVGGPSVPTSPVGQLLP--------- 
Nav1.9          ----SQTSRSSRMLAVFPANGKMHSTVDCNGVVSLVGGPSVPTSPVGQLLP--------- 
Nav1.2          ----SQASRASRVLPILPMNGKMHSAVDCNGVVSLVGGPSTLTS-AGQLLP--------- 
Nav1.3          ------------------------------------------------------------ 
Nav1.7          ----SQASRSP---PMLPVNGKMHSAVDCNGVVSLVDGRSALMLPNGQLLP--------- 
Nav1.6          YSGYSQGSRSSRIFPSLRRSVKRNSTVDCNGVVSLIGGPGSHIG--GRLLP--------- 
Nav1.4          ------------------------------------------------------------ 
Nav1.5          -------PSPGTSAPGHALHGKKNSTVDCNGVVSLLGAGDPEATSPGSHLLRPVMLEHPP 
                                                                             
 
Nav1.1          -EGTTTETEMRKRRSSSFHVSMDFLEDPSQRQRAMSIASILTNT-VEELEESRQKCPPCW 
Nav1.8          -EGTTTETEMRKRRSSSFHVSMDFLEDPSQRQRAMSIASILTNT-VEELEESRQKCPPCW 
Nav1.9          -EGTTTETEMRKRRSSSFHVSMDFLEDPSQRQRAMSIASILTNT-VEELEESRQKCPPCW 
Nav1.2          -EGTTTETEIRKRRSSSYHVSMDLLEDPTSRQRAMSIASILTNT-MEELEESRQKCPPCW 
Nav1.3          -NGTTTETEVRKRRLSSYQISMEMLEDSSGRQRAVSIASILTNT-MEELEESRQKCPPCW 
Nav1.7          -EGTTNQIHK-KRRCSSYLLSEDMLNDPNLRQRAMSRASILTNT-VEELEESRQKCPPWW 
Nav1.6          -EATT-EVEIKKKGPGSLLVSMDQLASYGRKDRINSIMSVVTNTLVEELEESQRKCPPCW 
Nav1.4          --------------------------EKGAPRQSSSGDSGISDA-MEELEEAHQKCPPWW 
Nav1.5          DTTTPSEEPGGPQMLTSQAPCVDGFEEPGARQRALSAVSVLTSA-LEELEESRHKCPPCW 
                                          .     :  *  * ::.: :*****:::**** * 
 
Nav1.1          YKFSNIFLIWDCSPYWLKVKHVVNLVVMDPFVDLAITICIVLNTLFMAMEHYPMTDHFNN 
Nav1.8          YKFSNIFLIWDCSPYWLKVKHVVNLVVMDPFVDLAITICIVLNTLFMAMEHYPMTDHFNN 
Nav1.9          YKFSNIFLIWDCSPYWLKVKHVVNLVVMDPFVDLAITICIVLNTLFMAMEHYPMTDHFNN 
Nav1.2          YKFANMCLIWDCCKPWLKVKHLVNLVVMDPFVDLAITICIVLNTLFMAMEHYPMTEQFSS 
Nav1.3          YRFANVFLIWDCCDAWLKVKHLVNLIVMDPFVDLAITICIVLNTLFMAMEHYPMTEQFSS 
Nav1.7          YRFAHKFLIWNCSPYWIKFKKCIYFIVMDPFVDLAITICIVLNTLFMAMEHHPMTEEFKN 
Nav1.6          YKFANTFLIWECHPYWIKLKEIVNLIVMDPFVDLAITICIVLNTLFMAMEHHPMTPQFEH 
Nav1.4          YKCAHKVLIWNCCAPWLKFKNIIHLIVMDPFVDLGITICIVLNTLFMAMEHYPMTEHFDN 
Nav1.5          NRLAQRYLIWECCPLWMSIKQGVKLVVMDPFTDLTITMCIVLNTLFMALEHYNMTSEFEE 
                 : ::  ***:*   *:..*. : ::*****.** **:**********:**: ** .*.  
 
Nav1.1          VLTVGNLVFTGIFTAEMFLKIIAMDPYYYFQEGWNIFDGFIVTLSLVELGLANVEGLSVL 
Nav1.8          VLTVGNLVFTGIFTAEMFLKIIAMDPYYYFQEGWNIFDGFIVTLSLVELGLANVEGLSVL 
Nav1.9          VLTVGNLVFTGIFTAEMFLKIIAMDPYYYFQEGWNIFDGFIVTLSLVELGLANVEGLSVL 
Nav1.2          VLSVGNLVFTGIFTAEMFLKIIAMDPYYYFQEGWNIFDGFIVSLSLMELGLANVEGLSVL 
Nav1.3          VLTVGNLVFTGIFTAEMVLKIIAMDPYYYFQEGWNIFDGIIVSLSLMELGLSNVEGLSVL 
Nav1.7          VLAIGNLVFTGIFAAEMVLKLIAMDPYEYFQVGWNIFDSLIVTLSLVELFLADVEGLSVL 
Nav1.6          VLAVGNLVFTGIFTAEMFLKLIAMDPYYYFQEGWNIFDGFIVSLSLMELSLADVEGLSVL 
Nav1.4          VLTVGNLVFTGIFTAEMVLKLIAMDPYEYFQQGWNIFDSIIVTLSLVELGLANVQGLSVL 
Nav1.5          MLQVGNLVFTGIFTAEMTFKIIALDPYYYFQQGWNIFDSIIVILSLMELGLSRMSNLSVL 
                :* :*********:*** :*:**:*** *** ******.:** ***:** *: :..**** 
 
Nav1.1          RSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKD 
Nav1.8          RSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKD 
Nav1.9          RSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKD 
Nav1.2          RSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKE 
Nav1.3          RSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKE 
Nav1.7          RSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKE 
Nav1.6          RSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKE 
Nav1.4          RSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKE 
Nav1.5          RSFRLLRVFKLAKSWPTLNTLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKNYSE 
                ******************* ************************************.*.: 
 
Nav1.1          CVCKIASDCQLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLTVFMMVMVI 
Nav1.8          CVCKIASDCQLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLTVFMMVMVI 
Nav1.9          CVCKIASDCQLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLTVFMMVMVI 
Nav1.2          CVCKISNDCELPRWHMHDFFHSFLIVFRVLCGEWIETMWDCMEVAGQTMCLTVFMMVMVI 
Nav1.3          CVCKINDDCTLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQTMCLIVFMLVMVI 
Nav1.7          CVCKINDDCTLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLIVYMMVMVI 
Nav1.6          CVCKINQDCELPRWHMHDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLIVFMMVMVI 
Nav1.4          CVCKIALDCNLPRWHMHDFFHSFLIVFRILCGEWIETMWDCMEVAGQAMCLTVFLMVMVI 
Nav1.5          LRD--SDSGLLPRWHMMDFFHAFLIIFRILCGEWIETMWDCMEVSGQSLCLLVFLLVMVI 
                       .  ****** ****:***:**:***************:**::** *:::**** 




Nav1.1          GNLVVLNLFLALLLSSFSADNLAATDDDNEMNNLQIAVDRMHKGVAYVKRKIYEFIQQSF 
Nav1.8          GNLVVLNLFLALLLSSFSADNLAATDDDNEMNNLQIAVDRMHKGVAYVKRKIYEFIQQSF 
Nav1.9          GNLVVLNLFLALLLSSFSADNLAATDDDNEMNNLQIAVDRMHKGVAYVKRKIYEFIQQSF 
Nav1.2          GNLVVLNLFLALLLSSFSSDNLAATDDDNEMNNLQIAVGRMQKGIDFVKRKIREFIQKAF 
Nav1.3          GNLVVLNLFLALLLSSFSSDNLAATDDDNEMNNLQIAVGRMQKGIDYVKNKMRECFQKAF 
Nav1.7          GNLVVLNLFLALLLSSFSSDNLTAIEEDPDANNLQIAVTRIKKGINYVKQTLREFILKAF 
Nav1.6          GNLVVLNLFLALLLSSFSADNLAATDDDGEMNNLQISVIRIKKGVAWTKLKVHAFMQAHF 
Nav1.4          GNLVVLNLFLALLLSSFSADSLAASDEDGEMNNLQIAIGRIKLGIGFAKAFLLGLLHGKI 
Nav1.5          GNLVVLNLFLALLLSSFSADNLTAPDEDREMNNLQLALARIQRGLRFVKRTTWDFCCGLL 
                ******************:*.*:* ::* : ****::: *:: *: :.*          : 
 
Nav1.1          IRKQKILDEIKPLDDLNNKKDSCMS--NHT-AEIGKDLDYLKDVNGTTSGIGT------- 
Nav1.8          IRKQKILDEIKPLDDLNNKKDSCMS--NHT-AEIGKDLDYLKDVNGTTSGIGT------- 
Nav1.9          IRKQKILDEIKPLDDLNNKKDSCMS--NHT-AEIGKDLDYLKDVNGTTSGIGT------- 
Nav1.2          VRKQKALDEIKPLEDLNNKKDSCIS--NHTTIEIGKDLNYLKDGNGTTSGIG-------- 
Nav1.3          FRKPKVIEIHE-----GNKIDSCMS--NNTGIEISKELNYLRDGNGTTSGVGT------- 
Nav1.7          SKKPKISREIRQAEDLNTKKENYIS--NHTLAEMSKGHNFLKE-KDKISGFG-------- 
Nav1.6          KQRE--ADEVKPLDELYEKKANCIA--NHTGADIHRNGDFQKNGNGTTSGIG-------- 
Nav1.4          LSPKDIMLSLGEADGAGEAGEAGET--APEDEKKEPPEEDLKKDNHILNHMG-------- 
Nav1.5          RQRPQKPAALAAQGQLPSCIATPYSPPPPETEKVPPTRKETRFEEGEQPGQGTPGDPEPV 
                                        :       .     .  :  :      *         
 
Nav1.1          -------GSSVEKYIIDESDYMSFINNPS------LTVTVPIAVGESDFENLNTEDFSSE 
Nav1.8          -------GSSVEKYIIDESDYMSFINNPS------LTVTVPIAVGESDFENLNTEDFSSE 
Nav1.9          -------GSSVEKYIIDESDYMSFINNPS------LTVTVPIAVGESDFENLNTEDFSSE 
Nav1.2          --------SSVEKYVVDESDYMSFINNPS------LTVTVPIAVGESDFENLNTEEFSSE 
Nav1.3          -------GSSVEKYVIDENDYMSFINNPS------LTVTVPIAVGESDFENLNTEEFSSE 
Nav1.7          --------SSVDKHLMEDSDGQSFIHNPS------LTVTVPIAPGESDLENMNAEELSSD 
Nav1.6          --------SSVEKYIIDE-DHMSFINNPN------LTVRVPIAVGESDFENLNTEDVSSE 
Nav1.4          --------LADGPPSSLELDHLNFINNPY------LTIQVPIASEESDLEMPTEEETDTF 
Nav1.5          CVPIAVAESDTDDQEEDEENSLGTEEESSKQQESQPVSGGPEAPPDSRTWSQVSATASSE 
                                 : :  .  .:.        .   * *  :*          .:  
 
Nav1.1          SDLEESKE--KLNE-------------SSSSSEGSTVDIGAPVE--EQPVVEPEETLEPE 
Nav1.8          SDLEESKE--KLNE-------------SSSSSEGSTVDIGAPVE--EQPVVEPEETLEPE 
Nav1.9          SDLEESKE--KLNE-------------SSSSSEGSTVDIGAPVE--EQPVVEPEETLEPE 
Nav1.2          SDMEESKE--KLN--------------ATSSSEGSTVDIGAPAEG-EQPEVEPEESLEPE 
Nav1.3          SELEESKE--KLN--------------ATSSSEGSTVDVVLPREG-EQAETEPEEDLKPE 
Nav1.7          SDSEYSKV--RLN--------------RSSSSECSTVDNPLPGEG-EEAEAEPMNSDEPE 
Nav1.6          SDPEGSKD--KLD--------------DTSSSEGSTIDIKPEVE--EVPVEQPEEYLDPD 
Nav1.4          SEPEDSKKPPQPLY-------------DGNSSVCSTADYKPPEEDPEEQAEENPEGEQPE 
Nav1.5          AEASASQADWRQQWKAEPQAPGCGETPEDSCSEGSTADMTNTAELLEQIPDLGQDVKDPE 
                :: . *:   :                  ..*  ** *     *  *       :  .*: 
 
Nav1.1          ACFTEGCVQRFKCCQINVEEGRGKQWWNLRRTCFRIVEHNWFETFIVFMILLSSGALAFE 
Nav1.8          ACFTEGCVQRFKCCQINVEEGRGKQWWNLRRTCFRIVEHNWFETFIVFMILLSSGALAFE 
Nav1.9          ACFTEGCVQRFKCCQINVEEGRGKQWWNLRRTCFRIVEHNWFETFIVFMILLSSGALAFE 
Nav1.2          ACFTEDCVRKFKCCQISIEEGKGKLWWNLRKTCYKIVEHNWFETFIVFMILLSSGALAFE 
Nav1.3          ACFTEGCIKKFPFCQVSTEEGKGKIWWNLRKTCYSIVEHNWFETFIVFMILLSSGALAFE 
Nav1.7          ACFTDGCVRRFSCCQVNIESGKGKIWWNIRKTCYKIVEHSWFESFIVLMILLSSGALAFE 
Nav1.6          ACFTEGCVQRFKCCQVNIEEGLGKSWWILRKTCFLIVEHNWFETFIIFMILLSSGALAFE 
Nav1.4          ECFTEACVQRWPCLYVDISQGRGKKWWTLRRACFKIVEHNWFETFIVFMILLSSGALAFE 
Nav1.5          DCFTEGCVRRCPCCAVDTTQAPGKVWWRLRKTCYHIVEHSWFETFIIFMILLSSGALAFE 
                 ***: *:::     :.  .. ** ** :*::*: ****.***:**::************ 
 
Nav1.1          DIYIDQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGYQTYFTNAWCWLDFLIVDVSLVS 
Nav1.8          DIYIDQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGYQTYFTNAWCWLDFLIVDVSLVS 
Nav1.9          DIYIDQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGYQTYFTNAWCWLDFLIVDVSLVS 
Nav1.2          DIYIEQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGFQVYFTNAWCWLDFLIVDVSLVS 
Nav1.3          DIYIEQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGFQTYFTNAWCWLDFLIVDVSLVS 
Nav1.7          DIYIERKKTIKIILEYADKIFTYIFILEMLLKWIAYGYKTYFTNAWCWLDFLIVDVSLVT 
Nav1.6          DIYIEQRKTIRTILEYADKVFTYIFILEMLLKWTAYGFVKFFTNAWCWLDFLIVAVSLVS 
Nav1.4          DIYIEQRRVIRTILEYADKVFTYIFIMEMLLKWVAYGFKVYFTNAWCWLDFLIVDVSIIS 
Nav1.5          DIYLEERKTIKVLLEYADKMFTYVFVLEMLLKWVAYGFKKYFTNAWCWLDFLIVDVSLVS 
                ***::.::.*: :******:***:*::****** ***:  :************* **::: 




Nav1.1          LTANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFW 
Nav1.8          LTANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFW 
Nav1.9          LTANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFW 
Nav1.2          LTANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFW 
Nav1.3          LVANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALVGAIPSIMNVLLVCLIFW 
Nav1.7          LVANTLGYSDLGPIKSLRTLRALRPLRALSRFEGMRVVVNALIGAIPSIMNVLLVCLIFW 
Nav1.6          LIANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALVGAIPSIMNVLLVCLIFW 
Nav1.4          LVANWLGYSELGPIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFW 
Nav1.5          LVANTLGFAEMGPIKSLRTLRALRPLRALSRFEGMRVVVNALVGAIPSIMNVLLVCLIFW 
                * ** **::::*.*****************************:***************** 
 
Nav1.1          LIFSIMGVNLFAGKFYHCINTTTGDR-FDIEDVNNHTDCLKLIE-RNETARWKNVKVNFD 
Nav1.8          LIFSIMGVNLFAGKFYHCINTTTGDR-FDIEDVNNHTDCLKLIE-RNETARWKNVKVNFD 
Nav1.9          LIFSIMGVNLFAGKFYHCINTTTGDR-FDIEDVNNHTDCLKLIE-RNETARWKNVKVNFD 
Nav1.2          LIFSIMGVNLFAGKFYHCINYTTGEM-FDVSVVNNYSECKALIE-SNQTARWKNVKVNFD 
Nav1.3          LIFSIMGVNLFAGKFYHCVNMTTGNM-FDISDVNNLSDCQALG----KQARWKNVKVNFD 
Nav1.7          LIFSIMGVNLFAGKFYECINTTDGSR-FPASQVPNRSECFALMN-VSQNVRWKNLKVNFD 
Nav1.6          LIFSIMGVNLFAGKYHYCFNETSEIR-FEIEDVNNKTECEKLMEGNNTEIRWKNVKINFD 
Nav1.4          LIFSIMGVNLFAGKFYYCINTTTSER-FDISEVNNKSECESLMH--TGQVRWLNVKVNYD 
Nav1.5          LIFSIMGVNLFAGKFGRCINQTEGDLPLNYTIVNNKSQCESLNL--TGELYWTKVKVNFD 
                **************:  *.* *     :    * * ::*  *         * ::*:*:* 
 
Nav1.1          NVGFGYLSLLQVATFKGWMDIMYAAVDSRNVELQPKYEESLYMYLYFVIFIIFGSFFTLN 
Nav1.8          NVGFGYLSLLQVATFKGWMDIMYAAVDSRNVELQPKYEESLYMYLYFVIFIIFGSFFTLN 
Nav1.9          NVGFGYLSLLQVATFKGWMDIMYAAVDSRNVELQPKYEESLYMYLYFVIFIIFGSFFTLN 
Nav1.2          NVGLGYLSLLQVATFKGWMDIMYAAVDSRNVELQPKYEDNLYMYLYFVIFIIFGSFFTLN 
Nav1.3          NVGAGYLALLQVATFKGWMDIMYAAVDSRDVKLQPVYEENLYMYLYFVIFIIFGSFFTLN 
Nav1.7          NVGLGYLSLLQVATFKGWTIIMYAAVDSVNVDKQPKYEYSLYMYIYFVVFIIFGSFFTLN 
Nav1.6          NVGAGYLALLQVATFKGWMDIMYAAVDSRKPDEQPKYEDNIYMYIYFVIFIIFGSFFTLN 
Nav1.4          NVGLGYLSLLQVATFKGWMDIMYAAVDSREKEEQPQYEVNLYMYLYFVIFIIFGSFFTLN 
Nav1.5          NVGAGYLALLQVATFKGWMDIMYAAVDSRGYEEQPQWEYNLYMYIYFVIFIIFGSFFTLN 
                *** ***:**********  ********   . ** :* .:***:***:*********** 
 
Nav1.1          LFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPGNKFQGMVFD 
Nav1.8          LFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPGNKFQGMVFD 
Nav1.9          LFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPGNKFQGMVFD 
Nav1.2          LFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPANKFQGMVFD 
Nav1.3          LFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPANKFQGMVFD 
Nav1.7          LFIGVIIDNFNQQKKKLGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPGNKIQGCIFD 
Nav1.6          LFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPLNKIQGIVFD 
Nav1.4          LFIGVIIDNFNQQKKKLGGKDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPQNKIQGMVYD 
Nav1.5          LFIGVIIDNFNQQKKKLGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPLNKYQGFIFD 
                ****************:**:****************************** ** ** ::* 
 
Nav1.1          FVTRQVFDISIMILICLNMVTMMVETDDQSEYVTTILSRINLVFIVLFTGECVLKLISLR 
Nav1.8          FVTRQVFDISIMILICLNMVTMMVETDDQSEYVTTILSRINLVFIVLFTGECVLKLISLR 
Nav1.9          FVTRQVFDISIMILICLNMVTMMVETDDQSEYVTTILSRINLVFIVLFTGECVLKLISLR 
Nav1.2          FVTKQVFDISIMILICLNMVTMMVETDDQSQEMTNILYWINLVFIVLFTGECVLKLISLR 
Nav1.3          FVTRQVFDISIMILICLNMVTMMVETDDQGKYMTLVLSRINLVFIVLFTGEFVLKLVSLR 
Nav1.7          LVTNQAFDISIMVLICLNMVTMMVEKEGQSQHMTEVLYWINVVFIILFTGECVLKLISLR 
Nav1.6          FVTQQAFDIVIMMLICLNMVTMMVETDTQSKQMENILYWINLVFVIFFTCECVLKMFALR 
Nav1.4          LVTKQAFDITIMILICLNMVTMMVETDNQSQLKVDILYNINMIFIIIFTGECVLKMLALR 
Nav1.5          IVTKQAFDVTIMFLICLNMVTMMVETDDQSPEKINILAKINLLFVAIFTGECIVKLAALR 
                :**.*.**: **.************.: *.     :*  **::*: :** * ::*: :** 
 
Nav1.1          HYYFTIGWNIFDFVVVILSIVGMFLAELIEKYFVSPTLFRVIRLARIGRILRLIKGAKGI 
Nav1.8          HYYFTIGWNIFDFVVVILSIVGMFLAELIEKYFVSPTLFRVIRLARIGRILRLIKGAKGI 
Nav1.9          HYYFTIGWNIFDFVVVILSIVGMFLAELIEKYFVSPTLFRVIRLARIGRILRLIKGAKGI 
Nav1.2          YYYFTIGWNIFDFVVVILSIVGMFLAELIEKYFVSPTLFRVIRLARIGRILRLIKGAKGI 
Nav1.3          HYYFTIGWNIFDFVVVILSIVGMFLAEMIEKYFVSPTLFRVIRLARIGRILRLIKGAKGI 
Nav1.7          HYYFTVGWNIFDFVVVIISIVGMFLADLIETYFVSPTLFRVIRLARIGRILRLVKGAKGI 
Nav1.6          HYYFTIGWNIFDFVVVILSIVGMFLADIIEKYFVSPTLFRVIRLARIGRILRLIKGAKGI 
Nav1.4          QYYFTVGWNIFDFVVVILSIVGLALSDLIQKYFVSPTLFRVIRLARIGRVLRLIRGAKGI 
Nav1.5          HYYFTNSWNIFDFVVVILSIVGTVLSDIIQKYFFSPTLFRVIRLARIGRILRLIRGAKGI 
                 **** .**********:****  *:::*:.**.***************:***::***** 




Nav1.1          RTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKREVGIDDMFNFETFGNSMIC 
Nav1.8          RTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKREVGIDDMFNFETFGNSMIC 
Nav1.9          RTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKREVGIDDMFNFETFGNSMIC 
Nav1.2          RTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKREVGIDDMFNFETFGNSMIC 
Nav1.3          RTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKKEAGIDDMFNFETFGNSMIC 
Nav1.7          RTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKKEDGINDMFNFETFGNSMIC 
Nav1.6          RTLLFALMMSLPALFNIGLLLFLVMFIFSIFGMSNFAYVKHEAGIDDMFNFETFGNSMIC 
Nav1.4          RTLLFALMMSLPALFNIGLLLFLVMFIYSIFGMSNFAYVKKESGIDDMFNFETFGNSIIC 
Nav1.5          RTLLFALMMSLPALFNIGLLLFLVMFIYSIFGMANFAYVKWEAGIDDMFNFQTFANSMLC 
                ***************************::****:****** * **:*****:**.**::* 
 
Nav1.1          LFQITTSAGWDGLLAPILNSKPPDCDPNKVNPGSSVKGDCGNPSVGIFFFVSYIIISFLV 
Nav1.8          LFQITTSAGWDGLLAPILNSKPPDCDPNKVNPGSSVKGDCGNPSVGIFFFVSYIIISFLV 
Nav1.9          LFQITTSAGWDGLLAPILNSKPPDCDPNKVNPGSSVKGDCGNPSVGIFFFVSYIIISFLV 
Nav1.2          LFQITTSAGWDGLLAPILNSGPPDCDPDKDHPGSSVKGDCGNPSVGIFFFVSYIIISFLV 
Nav1.3          LFQITTSAGWDGLLAPILNSAPPDCDPDTIHPGSSVKGDCGNPSVGIFFFVSYIIISFLV 
Nav1.7          LFQITTSAGWDGLLAPILNSKPPDCDPKKVHPGSSVEGDCGNPSVGIFYFVSYIIISFLV 
Nav1.6          LFQITTSAGWDGLLLPILN-RPPDCSLDKEHPGSGFKGDCGNPSVGIFFFVSYIIISFLI 
Nav1.4          LFEITTSAGWDGLLNPILNSGPPDCDPNLENPGTSVKGDCGNPSIGICFFCSYIIISFLI 
Nav1.5          LFQITTSAGWDGLLSPILNTGPPYCDPTLPNS-NGSRGDCGSPAVGILFFTTYIIISFLI 
                **:*********** ****  ** *.    :. .. .****.*::** :* :*******: 
 
Nav1.1          VVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFMEFEKLSQFAAALE 
Nav1.8          VVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFMEFEKLSQFAAALE 
Nav1.9          VVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFMEFEKLSQFAAALE 
Nav1.2          VVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFIEFAKLSDFADALD 
Nav1.3          VVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFIEFSKLSDFAAALD 
Nav1.7          VVNMYIAVILENFSVATEESTEPLSEDDFEMFYEVWEKFDPDATQFIEFSKLSDFAAALD 
Nav1.6          VVNMYIAIILENFSVATEESADPLSEDDFETFYEIWEKFDPDATQFIEYCKLADFADALE 
Nav1.4          VVNMYIAIILENFNVATEESSEPLGEDDFEMFYETWEKFDPDATQFIAYSRLSDFVDTLQ 
Nav1.5          VVNMYIAIILENFSVATEESTEPLSEDDFDMFYEIWEKFDPEATQFIEYSVLSDFADALS 
                *******:*****.******::**.****: *** ******:****: :  *::*. :*. 
 
Nav1.1          PPLNLPQPNKLQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEERFMAS 
Nav1.8          PPLNLPQPNKLQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEERFMAS 
Nav1.9          PPLNLPQPNKLQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEERFMAS 
Nav1.2          PPLLIAKPNKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEERFMAS 
Nav1.3          PPLLIAKPNKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEDRFMAS 
Nav1.7          PPLLIAKPNKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDSLRSQMEERFMSA 
Nav1.6          HPLRVPKPNTIELIAMDLPMVSGDRIHCLDILFAFTKRVLGDSGELDILRQQMEERFVAS 
Nav1.4          EPLRIAKPNKIKLITLDLPMVPGDKIHCLDILFALTKEVLGDSGEMDALKQTMEEKFMAA 
Nav1.5          EPLRIAKPNQISLINMDLPMVSGDRIHCMDILFAFTKRVLGESGEMDALKIQMEEKFMAA 
                 ** :.:** :.** :*****.**:***:*****:**.***:***:* *:  **::*::: 
 
Nav1.1          NPSKVSYQPITTTLKRKQEEVSAVIIQRAYRRHLLKRTVKQASFTYNKNKIK--GGANLL 
Nav1.8          NPSKVSYQPITTTLKRKQEEVSAVIIQRAYRRHLLKRTVKQASFTYNKNKIK--GGANLL 
Nav1.9          NPSKVSYQPITTTLKRKQEEVSAVIIQRAYRRHLLKRTVKQASFTYNKNKIK--GGANLL 
Nav1.2          NPSKVSYEPITTTLKRKQEEVSAIIIQRAYRRYLLKQKVKKVSSIYKKDKGK--ECDGTP 
Nav1.3          NPSKVSYEPITTTLKRKQEEVSAAIIQRNFRCYLLKQRLKNISSNYNKEAIK--GRIDLP 
Nav1.7          NPSKVSYEPITTTLKRKQEDVSATVIQRAYRRYRLRQNVKNISSIYIKDGDR--D-DDLL 
Nav1.6          NPSKVSYEPITTTLRRKQEEVSAVVLQRAYRGHLARR--------------------GFI 
Nav1.4          NPSKVSYEPITTTLKRKHEEVCAIKIQRAYRRHLLQRSMKQASYMYRHSHDG--SGDDAP 
Nav1.5          NPSKISYEPITTTLRRKHEEVSAMVIQRAFRRHLLQRSLKHASFLFRQQAGSGLSEEDAP 
                ****:**:******:**:*:*.*  :** :* :  ::                    .   
 
Nav1.1          IKEDMIIDRI-------NENSITEKTDLTMSTAACPPSYDRVTKPIVEK---------HE 
Nav1.8          IKEDMIIDRI-------NENSITEKTDLTMSTAACPPSYDRVTKPIVEK---------HE 
Nav1.9          IKEDMIIDRI-------NENSITEKTDLTMSTAACPPSYDRVTKPIVEK---------HE 
Nav1.2          IKEDTLIDKL-------NENSTPEKTDMTPSTTS-PPSYDSVTKPEKEK---------FE 
Nav1.3          IKQDMIIDKL-------NGNSTPEKTDGSSSTTS-PPSYDSVTKPDKEK---------FE 
Nav1.7          NKKDMAFDNV-------NENSSPEKTDATSSTTS-PPSYDSVTKPDKEK---------YE 
Nav1.6          CKKTTSNKLE-------NGGTHREKKESTPSTAS-LPSYDSVTKPEKEKQQR------AE 
Nav1.4          EKEGLLANTMSKMYGHENGNSSSPSPEEKGEAGDAGPTMGLMPISPSDT--A------WP 
Nav1.5          EREGLIAYVMSEN----FSRPLGPPSSSSISSTSFPPSYDSVTRATSDNLQVRGSDYSHS 
                 ::                 .     . . .:    *: . :. .  :.            




Nav1.1          QEGKDEKAKGK------- 
Nav1.8          QEGKDEKAKGK------- 
Nav1.9          QEGKDEKAKGK------- 
Nav1.2          KDKSEKEDKGKDIRESKK 
Nav1.3          KDKPEKESKGKEVRENQK 
Nav1.7          QDRTEKEDKGKDSKESKK 
Nav1.6          EGRRERAKRQKEVRESKC 
Nav1.4          PAPPPGQTVRPGVKESLV 
Nav1.5          EDLADFPPSPDRDRESIV 
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1. First Contact Initiative Grant from European Society of Cardiology 





1. Voltage Gated Sodium Channels: mutations, channelopathies and subtype 
specific targets 
Gowri Shankar Bagavananthem Andavan and Rosa Lemmens-Gruber 




 INSTITUTE YEAR 
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Schooling 
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SCIENTIFIC PAPERS 




2. Essential structural features of TNF-α lectin-like domain derived peptides 
for activation of amiloride-sensitive sodium current in A549 cells. 
Parastoo Hazemi, Susan J. Tzotzos, Bernhard Fischer, Gowri Shankar 
Bagavananthem Andavan, Hendrick Fischer, Helmut Pietschmann, Rudolf Lucas, 
Rosa Lemmens-Gruber. 
Journal of Medicinal Chemistry, 2010, 53(22):8021-9.  
 
3. Cyclodepsipeptides from marine sponges: natural agents for drug 
research. 
Gowri Shankar Bagavananthem Andavan and Rosa Lemmens-Gruber 
Marine Drugs, 2010, 8(3), 810-834. 
 
4. A Structural and Phylogenetic Analysis of Cytochrome P450 
B.A.Gowri Shankar, Michael Charleston, Michael Murray and David Hibbs 
International Proceedings of the 15th International Conference on Cytochrome P450: 
Biochemistry, Biophysics, Functional Genomics, 2007, 75-80. 
 
5. Ion-pairs in non-redundant protein structures 
B.A.Gowri Shankar, R.Sarani, Daliah Michael, P.Mridula, C.Vasuki Ranjani, 
G.Sowmiya, B.Vasundhar, P.Sudha, J.Jeyakanthan, D.Velmurugan and K.Sekar. J. 





1. ESC Congress 2010, 28 August - 1 September, Stockholm, Sweden. Title: 
Modulation of cardiac voltage gated sodium channel splice variants with its auxiliary 
subunit by Fyn tyrosine kinase.  
 
2. Frontiers in Cardiovascular Biology, Berlin, Germany, 16-19 July 2010, 
Title: Cardiac sodium channel variants and fyn tyrosine kinase modulation.  
 
3. XXth World Congress of the International Society of Heart Research 2010, 
May 13-16 2010, Kyoto, Japan. Title: Fyn tyrosine kinase modulation on 
cardiac voltage gated sodium channel splice variants.   
 
4. 54th Biophysical Society’s Annual Meeting at The Moscone Convention 
Center 20-24 February 2010, San Francisco, California. Title: Modulation of 
Nav1.5 varients by Src tyrosine kinase.  
POSTER  PRESENTATIONS 





5. 15th International Conference on Intelligent System for Molecular Biology 
(ISMB) Jointly with European Conference on Computational Biology 
(ECCB) on 21-25 July, 2007, Vienna, Austria.  
 
6. 11th Annual International Conference on Research in Computational 
Molecular Biology (RECOMB 2007), 21-25 April, 2007, San Francisco Bay, 
California.   
 
7. Fifth Asia-Pacific Bioinformatics Conference, 15-17 January, 2007, 
      Hong Kong.  
 
8. 4th Annual Rocky Mountain Bioinformatics Conference, 1-6 December, 
2006, Aspen/Snowmass, Colorado.  
 





1. Travel grant from the ESC Council on Basic Cardiovascular Science to 
attend ESC Congress 2010, Stockholm, Sweden. 
2. International ISHR Travel Grant to attend XXth World Congress of the 
International Society of heart Research 2010, Kyoto, Japan. 
3. International Travel Award from Biophysical Society to attend and present 
my data in 54
th
 Annual Meeting at San Francisco, California.  
4. Travel scholarship from RECOMB 2007 committee, to attend RECOMB 
2007 in San Francisco Bay, California, USA.  
5. BioinfoSummer 2006, ICE-EM Scholarship to attend summer symposium 
in Bioinformatics, ANU, Canberra; Australia.  
6. Travel scholarship to attend PhD Winter School in Data Mining &   
      Bioinformatics, Lorne, Victoria, Australia  
7. Travel scholarship to attend APAC Summer School in Computational 
Science 2006, Brisbane, Australia. 
8. Chief Minister Meritorious Award to students to continue their 










 Demonstrating Medicinal Chemistry PHAR2632 in Faculty of Pharmacy, 
University of Sydney. (March 2007 – June 2007) 
 Demonstrating Medicinal Chemistry PHAR2618 in Faculty of Pharmacy, 
University of Sydney. (July 2006 – November 2006) 
 
TEACHING  
